

ISSN 1881-7815 Online ISSN 1881-7823

BST

BioScience Trends

Volume 5 • Number 2 • 2011



www.biosciencetrends.com

BST

BioScience Trends



ISSN: 1881-7815

Online ISSN: 1881-7823

CODEN: BTIRCZ

Issues/Year: 6

Language: English

Publisher: IACMHR Co., Ltd.

BioScience Trends is one of a series of peer-reviewed journals of the International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) Group and is published bimonthly by the International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.) and supported by the IRCA-BSSA and Shandong University China-Japan Cooperation Center for Drug Discovery & Screening (SDU-DDSC).

BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.

BioScience Trends publishes Original Articles, Brief Reports, Reviews, Policy Forum articles, Case Reports, News, and Letters on all aspects of the field of life science. All contributions should seek to promote international collaboration.

Editorial Board

Editor-in-Chief:

Masatoshi MAKUUCHI
Japanese Red Cross Medical Center, Tokyo, Japan

Co-Editors-in-Chief:

Xue-Tao CAO
Chinese Academy of Medical Sciences, Beijing, China
Rajendra PRASAD
King George's Medical University, Lucknow, India
Arthur D. RIGGS
Beckman Research Institute of the City of Hope, Duarte, CA, USA

Chief Director & Executive Editor:

Wei TANG
The University of Tokyo, Tokyo, Japan

Managing Editor:

Munehiro NAKATA
Tokai University, Hiratsuka, Japan

Senior Editors:

Xunjia CHENG
Fudan University, Shanghai, China
Yoko FUJITA-YAMAGUCHI
Tokai University, Hiratsuka, Japan
Kiyoshi KITAMURA
The University of Tokyo, Tokyo, Japan

Chushi KUROIWA
Yotsukaidou Tokushukai Medical Center, Yotsukaido, Japan
Misao MATSUSHITA
Tokai University, Hiratsuka, Japan
Takashi SEKINE
The University of Tokyo, Tokyo, Japan
Yasuhiko SUGAWARA
The University of Tokyo, Tokyo, Japan

Web Editor:

Yu CHEN
The University of Tokyo, Tokyo, Japan

Proofreaders:

Curtis BENTLEY
Roswell, GA, USA
Christopher HOLMES
The University of Tokyo, Tokyo, Japan
Thomas R. LEBON
Los Angeles Trade Technical College, Los Angeles, CA, USA

Editorial Office

Pearl City Koishikawa 603,
2-4-5 Kasuga, Bunkyo-ku,
Tokyo 112-0003, Japan
Tel: 03-5840-8764
Fax: 03-5840-8765
E-mail: office@biosciencetrends.com

BioScience Trends

Editorial and Head Office

Pearl City Koishikawa 603, 2-4-5 Kasuga, Bunkyo-ku,
Tokyo 112-0003, Japan

Tel: 03-5840-8764, Fax: 03-5840-8765
E-mail: office@biosciencetrends.com
URL: www.biosciencetrends.com

Editorial Board Members

Girdhar G. AGARWAL (Lucknow, India)	Jinxiang Han (Ji'nan, China)	Yutaka MATSUYAMA (Tokyo, Japan)	Sumihito TAMURA (Tokyo, Japan)
Hirotsugu AIGA (Geneva, Switzerland)	Na HE (Shanghai, China)	Qingyue MENG (Beijing, China)	Puay Hoon TAN (Singapore, Singapore)
Hidechika AKASHI (Tokyo, Japan)	David M. HELFMAN (Daejeon, Korea)	Mark MEUTH (Sheffield, UK)	John TERMINI (Duarte, CA, USA)
Moazzam ALI (Geneva, Switzerland)	De-Xing HOU (Kagoshima, Japan)	Yutaka MOROHOSHI (Tokyo, Japan)	Usa C. THISYAKORN (Bangkok, Thailand)
Michael E. BARISH (Duarte, CA, USA)	Sheng-Tao HOU (Ottawa, Canada)	Satoko NAGATA (Tokyo, Japan)	Toshifumi TSUKAHARA (Nomi, Japan)
Boon-Huat BAY (Singapore, Singapore)	Yong HUANG (Ji'ning, China)	Miho OBA (Odawara, Japan)	Kohjiro UEKI (Tokyo, Japan)
Yasumasa BESSHO (Nara, Japan)	Hirofumi INAGAKI (Tokyo, Japan)	Xianjun QU (Ji'nan, China)	Masahiro UMEZAKI (Tokyo, Japan)
Generoso BEVILACQUA (Pisa, Italy)	Masamine JIMBA (Tokyo, Japan)	Sergei N. RODIN (Duarte, CA, USA)	Junming WANG (Jackson, MS, USA)
Shiuan CHEN (Duarte, CA, USA)	Kimitaka KAGA (Tokyo, Japan)	John J. ROSSI (Duarte, CA, USA)	Ling WANG (Shanghai, China)
Yuan CHEN (Duarte, CA, USA)	Ichiro KAI (Tokyo, Japan)	Carlos SAINZ-FERNANDEZ (Santander, Spain)	Stephen G. WARD (Bath, UK)
Naoshi DOHMAE (Wako, Japan)	Kazuhiro KAKIMOTO (Osaka, Japan)	Takehito SATO (Isehara, Japan)	Hisashi WATANABE (Tokyo, Japan)
Zhen FAN (Houston, TX, USA)	Kiyoko KAMIBEPPU (Tokyo, Japan)	Akihito SHIMAZU (Tokyo, Japan)	Masatake YAMAUCHI (Chiba, Japan)
Ding-Zhi FANG (Chengdu, China)	Bok-Luel LEE (Busan, Korea)	Judith SINGER-SAM (Duarte, CA, USA)	Yun YEN (Duarte, CA, USA)
Yosiharu FUKUDA (Ube, Japan)	Mingjie LI (St. Louis, MO, USA)	Raj K. SINGH (Dehradun, India)	George W-C. YIP (Singapore, Singapore)
Rajiv GARG (Lucknow, India)	Ren-Jang LIN (Duarte, CA, USA)	Junko SUGAMA (Kanazawa, Japan)	Benny C-Y ZEE (Hong Kong, China)
Ravindra K. GARG (Lucknow, India)	Hongxiang LOU (Ji'nan, China)	Hiroshi TACHIBANA (Isehara, Japan)	(as of April 2011)
Makoto GOTO (Yokohama, Japan)	Daru LU (Shanghai, China)	Tomoko TAKAMURA (Tokyo, Japan)	
Demin HAN (Beijing, China)	Duan MA (Shanghai, China)	Tadatoshi TAKAYAMA (Tokyo, Japan)	

Brief Reports

- 46 - 51** **Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells.**
Fangcang Yu, Yazhou Cui, Xiaoyan Zhou, Xiumei Zhang, Jinxiang Han
- 52 - 56** **Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth.**
Yoshinori Inagaki, Fanghua Qi, Jianjun Gao, Xianjun Qu, Kiyoshi Hasegawa, Yasuhiko Sugawara, Wei Tang, Norihiro Kokudo
- 57 - 60** **Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis.**
Junichi Togashi, Yasuhiko Sugawara, Sumihito Tamura, Junichi Kaneko, Noriyo Yamashiki, Taku Aoki, Kiyoshi Hasegawa, Norihiro Kokudo

Original Articles

- 61 - 68** **Content analysis of school textbooks on health topics: A systematic review.**
Marino Nomoto, Daisuke Nonaka, Tetsuya Mizoue, Jun Kobayashi, Masamine Jimba
- 69 - 76** **Medical students' choice of specialty and factors determining their choice: A cross-sectional questionnaire survey in Melaka-Manipal Medical College, Malaysia.**
Yu Wei Chew, Sudeash Rajakrishnan, Chin Aun Low, Prakash Kumar Jayapalan, Chandrashekhar T. Sreeramareddy
- 77 - 82** **Impaired function of bone marrow-derived endothelial progenitor cells in murine liver fibrosis.**
Katsuya Shirakura, Haruchika Masuda, Sang-Mo Kwon, Syotaro Obi, Rie Ito, Tomoko Shizuno, Yusuke Kurihara, Tetsuya Mine, Takayuki Asahara
- 83 - 88** **Immunohistochemical characterization of the cellular infiltrate in discoid lupus erythematosus.**
Yong Xie, Masatoshi Jinnin, Xiaoyong Zhang, Shoji Wakasugi, Takamitsu Makino, Yuji Inoue, Satoshi Fukushima, Shinichi Masuguchi, Keisuke Sakai, Hironobu Ihn

CONTENTS

(Continued)

Guide for Authors

Copyright

Osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclast-like cells

Fangcang Yu, Yazhou Cui, Xiaoyan Zhou, Xiumei Zhang, Jinxiang Han*

Shandong Academy of Medical Sciences, Shandong Medical Biotechnological Center, Key Laboratory for Biotech Drugs of the Ministry of Health, Ji'nan, China.

Summary

Osteoclasts secrete factors that may promote mesenchymal stem cell mineralization *in vitro*. Fibroblasts are the most common cells in connective tissue and are involved in the process of exotic ossification in many diseases such as ankylosing spondylitis. The purpose of this study was to investigate whether osteoclast-like cells would induce the osteogenic differentiation of fibroblasts *in vitro*. In the present study, osteoclast-like cells (OLCs) were generated by CD14⁺ cells from human peripheral blood. Fibroblasts were primarily cultured from spinal ligaments. After treatment with conditioned medium of OLCs, the level of alkaline phosphatase (ALP) and mineralization of fibroblasts increased significantly. cDNA microarray analysis identified a set of differentially expressed mRNA associated with signal transduction, cell differentiation, and bone formation, and microarray analysis of microRNA expression profiles revealed a group of microRNAs, including hsa-miR-20a, hsa-miR-300, hsa-miR-185, hsa-miR-30d, hsa-miR-320a, hsa-miR-130b, hsa-miR-33a, hsa-miR-155, and hsa-miR-222, that were significantly down-regulated. These microRNAs were predicted to have an inhibitory effect on genes associated with osteogenic differentiation, such as BMP2, Osteocalcin, and Runx2. The current results suggest that osteoclasts might induce the osteogenic differentiation of fibroblasts *in vitro* and that miRNA may play an important role in regulation of the cell-cell interaction between osteoclasts and fibroblasts.

Keywords: Mineralization, cell-cell interaction, mRNA, microRNA, microarray

1. Introduction

The osteoclast (OC) is a tissue-specific macrophage polykaryon derived from the monocyte/macrophage precursor cells at or near the bone surface (1). Fibroblasts are the most common cells of the connective tissue and are derived from primitive mesenchyme (2,3). Fibroblasts are mainly responsible for the production and turnover of extracellular matrix (ECM), which is rich in collagen and other macromolecules, and play an important role in trauma repair and pathologic ectopic ossification in some

diseases, such as ankylosing spondylitis and systemic sclerosis (3,4). The mechanisms of osteogenic differentiation of fibroblasts and ossification have not been clarified. Fibroblasts and osteoblasts are from the same lineage (5). The widely accepted view is that osteoclasts can promote the differentiation of osteoblasts. Conditioned medium derived from human osteoclasts induces preosteoblasts to form bone-like nodules (6). Gene array analysis, in combination with loss-of-function studies, revealed that mature osteoclasts secrete Wnt10b, sphingosine 1-phosphate, and bone morphogenetic protein-6 (BMP6) and might promote osteoblast mineralization (7). Thus, osteoclasts may play a key role in the process of inducing heterotopic ossification mediated by fibroblasts. The objective of the present study was to evaluate the effect that osteoclasts have on inducing the osteogenic differentiation of fibroblasts and initially investigate the mechanism by which this occurs.

*Address correspondence to:

Dr. Jinxiang Han, Shandong Academy of Medical Sciences, Jing-shi Road No. 18877, Ji'nan 250062, Shandong, China.
e-mail: samshjx@sina.com

2. Materials and Methods

2.1. Primary culture of ligament fibroblasts

Interspinous ligaments were obtained with the informed consent of patients with lumbar spondylolisthesis. Fibroblasts were primarily cultured from ligaments with the collagen collagenase digestion method using collagenase I (Sigma-Aldrich China, Shanghai, China). Fibroblasts were cultured in Dulbecco's Modification of Eagle's Medium (DMEM) (HiClone, Logan, Utah, USA) containing 10% Fetal Bovine Serum (FBS) (Invitrogen, Carlsbad, California, USA), 100 U/mL penicillin (Invitrogen, Carlsbad, California, USA), and 100 µg/mL streptomycin (Invitrogen, Carlsbad, California, USA) and were incubated in a humidified atmosphere (37°C, 5% CO₂). The culture medium was changed after 24 h and every other day thereafter.

2.2. Generating osteoclast-like cells from peripheral blood

Peripheral blood was drawn from normal volunteers and supplemented with the anticoagulant ethylenediaminetetraacetic acid (EDTA). CD14⁺ cells were isolated by Ficoll-Paque (GE Healthcare, Salt Lake City, Utah, USA) density gradient centrifugation followed by isolation with anti-CD14 immunomagnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). This was done in accordance with the manufacturer's instructions. The isolated CD14⁺ cells were seeded in DMEM containing 10% FBS, 100 U/mL penicillin, and 100 µg/mL streptomycin. Five × 10⁵/well CD14⁺ cells were added in 24-well containing either bovine bone slices (8 mm × 8 mm × 0.2 mm, sterilized by ultraviolet radiation) or glass cover slips (8 mm × 8 mm) and incubated at 37°C with 5% CO₂ in a humidified incubator. The medium was supplemented with 25 ng/mL macrophage colony-stimulating factor (M-CSF) (PeproTech, Rocky Hill, New Jersey, USA) and 30 ng/mL receptor activator of nuclear factor kappa-B ligand (RANKL) (PeproTech, Rocky Hill, New Jersey, USA). Cultures were incubated and culture medium containing the factors was replenished every 3 d. After 21 d of culturing, the characteristics of osteoclasts were identified. Using the same method, more osteoclasts were cultured in a 25 cm² cell culture flasks (without bovine bone slice or glass cover slips) in order to harvest conditioned medium.

Observation of morphological characteristics: An inverted phase contrast microscope was used to observe the characteristics of multinucleate cells. Tartrate-resistant acid phosphatase (TRAP) staining: Histochemical staining for TRAP, a marker of osteoclasts, was carried out with an Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich China, Shanghai, China). Assessment of bone resorption

function: Bovine bone slices with cultured OLCs were subjected to fixation, dehydration, isoamyl acetate replacement, routine critical point drying, and plating platinum. Cells were then observed and photographs were taken with a Hitachi S570 scanning electron microscope.

2.3. Conditioned medium of osteoclast-like cells treatment

After OLCs were cultured for 21 d, addition of M-CSF and RANKL to medium was halted and the medium was refreshed every 2 d. The conditioned medium was collected and centrifuged to remove cells that were suspended in the medium. Fibroblasts were conditioned in OLC-conditioned medium and medium was refreshed every 2 d. Fibroblasts were cultured in normal medium (DMEM containing 10% FBS, 100 U/mL penicillin and 100 µg/mL streptomycin, without M-CSF and RANKL) as a control.

2.4. Assessment of fibroblast mineralization

After fixation with 95% alcohol, a BCIP/NBT Alkaline Phosphatase Color Development Kit (Beyotime, Nantong Jiangsu, China) was used to detect the expression of ALP. Cultures were fixed and stained for mineralization with Alizarin red. Alizarin red was eluted with 10% cetylpyridinium chloride, and levels were quantified in comparison to a standard curve. To obtain a normal distribution and equal variance between the two test groups (four wells of OLC-conditioned medium (OCMT) fibroblasts and four wells of control fibroblasts), all data were log₁₀-transformed. When only two groups were compared, an unpaired Student's *t*-test was used to test significance.

2.5. Microarray detection of changes in the mRNA and miRNA expression profiles of fibroblasts

2.5.1. mRNA microarray

Total RNA from each sample was quantified using the NanoDrop 1000 and RNA integrity was assessed using standard denaturing agarose gel electrophoresis. About 5 µg of total RNA from each sample was used for labeling and array hybridization in the following steps: 1) Reverse transcription with an Invitrogen Superscript ds-cDNA synthesis kit; 2) ds-cDNA labeling with a NimbleGen one-color DNA labeling kit; 3) Array hybridization using the NimbleGen Hybridization System and then washing with the NimbleGen wash buffer kit; 4) Array scanning using the Axon GenePix 4000B microarray scanner (Molecular Devices Corporation). Scanned images (TIFF format) were then imported into NimbleScan software (version 2.5) for grid alignment and expression data analysis.

2.5.2. miRNA microarray

Total RNA are harvested using TRIzol (Invitrogen, Carlsbad, California, USA) and an RNeasy mini kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. After RNA measurement using the NanoDrop instrument, the samples were labeled using the miRCURY™Hy3™/Hy5™ Power labeling kit and hybridized on the miRCURY™ LNA Array (v.14.0). The samples were hybridized on a hybridization station following the scheme outlined in sample submission. Scanning was performed with the Axon GenePix 4000B microarray scanner. GenePix pro V6.0 was used to read the raw intensity of the image.

2.5.3. Data analysis

Expression data were normalized through quantile normalization and the Robust Multichip Average (RMA) algorithm included in the NimbleScan software. The Probe level files and Gene level files were generated after normalization. The 2 gene level files were imported into Agilent GeneSpring GX software (version 11.5) for further analysis. Genes with values greater than or equal to the lower cut-off (50.0) in all samples ("All Target Values") were chosen for data analysis. Differentially expressed genes were identified through Fold Change filtering. Pathway analysis and GO Analysis were performed to reveal the biological

functions of this subset of differentially expressed genes. Finally, hierarchical clustering was performed to provide distinguishable gene expression profiling among samples. microRNA targets were predicted by three programs: miRanda, PicTar, and Target-Scan. The overlap of the results predicted by three programs served as the acceptable target genes of microRNA.

3. Results and Discussion

3.1. Primary cultured fibroblasts and OLCs with characteristics of osteoclasts

Fibroblasts were generated by spinal ligaments (Figure 1A). After 21 d of induction of M-CSF and RANKL, osteoclast-like cells had the characteristics of osteoclasts, such as a large volume, irregular shape, pseudopodium and multinucleation (Figure 1B), and high TRAP positivity (Figure 1C). Under SEM observation, osteoclast-like cells were found to have bone resorption ability since there were absorption lacunae below the osteoclasts (Figure 1D).

3.2. Osteogenic differentiation of fibroblasts induced by OLC-conditioned medium

After 21 d of induction with OLC-conditioned medium, the ALP positivity of fibroblasts was approximately 40% (Figure 2B). In contrast, the ALP




Figure 1. Primary cultured ligament fibroblasts and osteoclast-like cells generated by peripheral blood mononuclear cells. (A) Fibroblasts generated by ligaments; (B) Multinuclear osteoclast-like cells; (C) TRAP staining of OLC; (D) Bone resorption of OLC.




Figure 2. Results of Alkaline Phosphatase Color Development. (A) Control; (B) Fibroblasts treated with OLC-conditioned medium; (C) Comparison of ALP positivity of the control and fibroblasts treated with OLC-conditioned medium. $p < 0.05$.




Figure 3. Effect of osteoclast-conditioned media on fibroblast mineralization. (A) Control; (B) Fibroblasts treated with OLC-conditioned medium; (C) Comparison of the mineralization of control and fibroblasts treated with OLC-conditioned medium. $p < 0.05$.

positivity of the control group was only 5% (Figure 2A). Conditioned media from osteoclast-like cells significantly increased mineralization of fibroblast cultures (Figure 3).

3.3. mRNA microarray data analysis

Compared to fibroblasts cultured in normal medium, fibroblasts treated with OCMT had 522 genes up-regulated more than 2-fold and 415 genes down-regulated more than 2-fold. The scatterplot is a visualization of the variation between chips (Figure 4). GO analysis revealed that the differentially expressed genes were mainly involved in bioprocesses like response to stimulus, signal transduction, cell activation, myeloid cell differentiation, calcium-mediated signaling, cell adhesion, and immune response. The cellular components of differentially expressed genes were mainly distributed in MHC protein complex, plasmolemma, the extracellular region, extracellular space, collagen, and the like. The molecular function of differentially expressed genes was mainly related to MHC class II receptor activity, protein complex binding, signal transducer activity, chemokine activity, and collagen binding. Pathway analysis revealed that differentially expressed genes mainly participated in pathways, such as cell adhesion molecules, leukocyte transendothelial migration chemokine signaling pathways, cytokine-cytokine receptor interaction, and Toll-like receptor signaling pathways.




Figure 4. Scatter-plot for ocmt-cont (mRNA). Scatter-plot to assess the variation (or reproducibility) between mRNA chips. The axes of the scatter-plot are the averaged normalized signal values of the samples in each group (\log_2 scaled). The green lines are Fold Change Lines (The default fold change value given is 2.0). Genes above the top green line and below the bottom green are 2-fold change genes.

3.4. miRNA microarray data analysis

Compared to fibroblasts cultured in normal medium, fibroblasts treated with OCMT had 28 miRNAs up-regulated more than 2-fold and 59 miRNAs down-regulated more than 2-fold. Target genes prediction software analysis revealed that among the down-regulated miRNAs the target genes of miR-20a and hsa-miR-300 included BMP2. Osteocalcin (bone

gamma-carboxyglutamate protein, BGLAP) was one of the target genes of hsa-miR-185 while hsa-miR-30d, hsa-miR-320a, hsa-miR-20a, hsa-miR-130b, hsa-miR-33a, hsa-miR-155, and hsa-miR-222 all targeted Runx2. These genes are all related to osteogenic differentiation.

Mature osteoclasts secreted products that promote fibroblast mineralization and caused a series of changes in mRNA and miRNA expression profiles of fibroblasts. Through cytokine-cytokine receptor interaction and regulation of signaling pathways, the products secreted by osteoclast-like cells may affect the metabolism and differentiation of fibroblasts. The current microarray analysis suggests that the Toll-like receptor signaling pathway may play an important role in these processes. A recent study has found that the Toll-like receptor is associated with osteogenic differentiation of stromal cells (8).

No previous reports have described the effects of osteoclasts on fibroblasts, but studies have found that fibroblasts can induce differentiation of precursor cells into mature osteoclasts. Bloemen and colleagues (9) found that gene expression of intercellular adhesion molecule-1 (ICAM-1) and osteoclastogenesis-related genes (RANKL, RANK, TNF- α , and IL-1b) was highly up-regulated in co-cultures with fibroblasts. The current study has shown that conditioned medium of osteoclast-like cells can influence the adhesion molecule pathway of fibroblasts. Hypoxia-induced ID-2 may contribute to joint destruction in RA patients by promoting synovial fibroblast-dependent osteoclastogenesis (10). Moreover, oestrogen can inhibit osteoclast formation induced by periodontal ligament fibroblasts (11). The current study suggests that there is interaction between osteoclasts and fibroblasts. Fibroblasts can induce osteoclastogenesis and osteoclasts induce osteogenic differentiation of fibroblasts. These findings will help to understand the pathomechanism of ectopic ossification mediated by fibroblasts.

miRNAs are small noncoding RNAs that significantly regulate the translation of protein coding genes in higher organisms (12-14). These small RNAs (approximately 22 nucleotides) are involved in almost every biological process, including early development, lineage commitment, growth and differentiation, cell death, and metabolic control (12-16). Each miRNA targets an average of 100-200 genes by binding preferentially to their 3' UTRs by means of partial sequence complementarity (17). miRNAs engage in a wide diversity of biological processes by coordinating with transcription factors, and this kind of cross-layer coregulation may have greater specificity than intra-layer coregulation (18). The current study has suggested that microRNA plays an important role in the osteogenesis of mesenchymal stem cells (19). Changes in microRNA expression profiles were examined in

the current study during the process of osteogenic differentiation induced by OLC-conditioned medium. This study also found that microRNAs such as hsa-miR-20a, hsa-miR-300, hsa-miR-185, hsa-miR-30d, hsa-miR-320a, hsa-miR-130b, hsa-miR-33a, hsa-miR-155 and hsa-miR-222 may play a key role by regulating the expression of BMP2, Osteocalcin, Runx2, in the process of osteogenic differentiation.

The present study investigated the effects of osteoclast-like cells on induction of fibroblast mineralization without direct cell-to-cell contact. This study also identified a set of mRNA and miRNA differentially regulated during fibroblast mineralization. However, the factors secreted by osteoclast-like cells that influence signal transduction and that regulate expression miRNA and their target genes remain unclear. More research is needed to determine the precise mechanism of these processes.

References

- Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature*. 2003; 423:337-342.
- Togo S, Sato T, Sugiura H, Wang X, Basma H, Nelson A, Liu X, Bargar TW, Sharp JG, Rennard SI. Differentiation of embryonic stem cells into fibroblast-like cells in three-dimensional type I collagen gel cultures. *In Vitro Cell Dev Biol Anim*. 2011; 47:114-124.
- Ogawa M, LaRue AC. Origin of fibroblast colony-forming units. *Exp Hematol*. 2007; 35:1319-1320.
- Schett G. Bone formation versus bone resorption in ankylosing spondylitis. *Adv Exp Med Biol*. 2009; 649:114-121.
- Ducy P, Schinke T, Karsenty G. The osteoblast: A sophisticated fibroblast under central surveillance. *Science*. 2000; 289:1501-1504.
- Karsdal MA, Neutzsky-Wulff AV, Dziegiel MH, Christiansen C, Henriksen K. Osteoclasts secrete non-bone derived signals that induce bone formation. *Biochem Biophys Res Commun*. 2008; 366:483-488.
- Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. *Proc Natl Acad Sci U S A*. 2008; 105:20764-20769.
- Yang X, Fullerton DA, Su X, Ao L, Cleveland JC Jr, Meng X. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. *J Am Coll Cardiol*. 2009; 53:491-500.
- Bloemen V, Schoenmaker T, de Vries TJ, Everts V. Direct cell-cell contact between periodontal ligament fibroblasts and osteoclast precursors synergistically increases the expression of genes related to osteoclastogenesis. *J Cell Physiol*. 2010; 222:565-573.
- Kurowska-Stolarska M, Distler JH, Jüngel A, Rudnicka W, Neumann E, Pap T, Wenger RH, Michel BA, Müller-Ladner U, Gay RE, Maslinski W, Gay S, Distler O. Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-

- dependent osteoclastogenesis. *Arthritis Rheum.* 2009; 60:3663-3675.
11. Wattanaroonwong N, Schoenmaker T, de Vries TJ, Everts V. Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. *Arch Oral Biol.* 2011; 56:212-219.
 12. Hassan MQ, Gordon JA, Beloti MM, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. A network connecting Runx2, SATB2, and the miR-23a~27a~24-2 cluster regulates the osteoblast differentiation program. *Proc Natl Acad Sci U S A.* 2010; 107:19879-19884.
 13. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. *Cell.* 2004; 116:281-297.
 14. Pawlicki JM, Steitz JA. Nuclear networking fashions pre-messenger RNA and primary microRNA transcripts for function. *Trends Cell Biol.* 2010; 20:52-61.
 15. Li Z, Hassan MQ, Volinia S, van Wijnen AJ, Stein JL, Croce CM, Lian JB, Stein GS. A microRNA signature for a BMP2-induced osteoblast lineage commitment program. *Proc Natl Acad Sci U S A.* 2008; 105:13906-13911.
 16. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. *J Biol Chem.* 2009; 284:15676-15684.
 17. Gennarino VA, Sardiello M, Mutarelli M, Dharmalingam G, Maselli V, Lago G, Banfi S. HOCTAR database: A unique resource for microRNA target prediction. *Gene.* 2011; [Epub ahead of print].
 18. Chen CY, Chen ST, Fuh CS, Juan HF, Huang HC. Coregulation of transcription factors and microRNAs in human transcriptional regulatory network. *BMC Bioinformatics.* 2011; 12(Suppl 1):S41.
 19. Kim YJ, Jung JS. Methods for analyzing microRNA expression and function during osteogenic differentiation of human adipose tissue-derived mesenchymal stem cells. *Methods Mol Biol.* 2011; 702:401-418.

(Received April 8, 2011; Revised April 13, 2011; Accepted April 18, 2011)

Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth

Yoshinori Inagaki¹, Fanghua Qi¹, Jianjun Gao^{1,2}, Xianjun Qu², Kiyoshi Hasegawa¹, Yasuhiko Sugawara¹, Wei Tang^{1,2,*}, Norihiro Kokudo¹

¹ Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;

² China-Japan Cooperation Center for Drug Discovery & Screen, Shandong University, Ji'nan, China.

Summary

c-Met, a type of receptor tyrosine kinase, may be significantly associated with the progression of hepatocellular carcinoma (HCC). In addition, des- γ -carboxyprothrombin (DCP) has been found to interact with c-Met and activate HCC cell growth. Therefore, the functional inhibition of c-Met expressed on HCC cells should arrest HCC cell growth. The present study found that the c-Met inhibitor SU11274 suppressed HCC cell growth by inhibiting the activation of c-Met. Furthermore, this inhibitor also neutralized the activation of HCC cell growth resulting from the addition of DCP. These results suggest that the functional inhibition of c-Met might be a target for the development of chemotherapeutic agents for HCC, and especially those that are positive for expression of DCP.

Keywords: c-Met, hepatocellular carcinoma (HCC), inhibitor, growth, des- γ -carboxyprothrombin (DCP)

1. Introduction

c-Met is a type of receptor tyrosine kinase expressed on the membranes of various cells (1). Hepatocyte growth factor (HGF), also known as scatter factor (SF), has been identified as the ligand for c-Met (2), and their interaction can activate the kinase activity of c-Met to trigger various cellular events, *e.g.* tissue regeneration, cell proliferation, and invasion (3). The phosphorylation of c-Met and subsequent activation of various downstream signal transduction pathways may play a significant role in the progression of hepatocellular carcinoma (HCC) (4-6). Several clinical studies noted overexpression of c-Met in HCC tissue compared to surrounding non-cancerous liver tissue (7-9), and this overexpression was suggested to correlate with

worse behavior of HCC (8). Furthermore, the down-regulation of c-Met expression by transfecting siRNA suppressed the proliferation and invasion of an HCC cell line (10,11). Thus, the expression of c-Met was found to be associated with the progression of HCC and its inhibition may contribute to the development of chemotherapy for HCC. Little research, however, has analyzed the inhibitory effect of c-Met on HCC cells by way of small-molecular compounds.

Des- γ -carboxyprothrombin (DCP), also referred to as protein induced by vitamin K absence or antagonist II (PIVKA-II), is known to be an effective tumor marker for HCC (12-14). This tumor marker is regularly used in clinical diagnosis to screen patients with primary HCC and to monitor the recurrence of HCC after curative therapy (15,16). While extensive scientific evidence has been assembled to indicate the clinicopathological significance of DCP, a high level of DCP in the sera of patients with HCC was significantly associated with the presence of vascular invasion followed by the presence of intrahepatic metastasis (16-18). Thus, DCP may serve to predict a worse prognosis of patients with HCC. Additionally, recent molecular biological studies on DCP have

*Address correspondence to:

Dr. Wei Tang, Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
e-mail: TANG-SUR@h.u-tokyo.ac.jp

revealed that DCP activates HCC cell growth (19,20). Gao *et al.* demonstrated that the proliferation of HCC cells increased as a result of DCP in a dose- and time-dependent manner (19). In addition, this action of DCP was also detected *in vivo* analyses using a nude mouse model with HCC cell xenograft (19). A biochemical study performed by Suzuki *et al.* showed that DCP can increase the DNA synthesis of HCC cells *via* the activation of c-Met-Janus kinase (JAK)-signal transducers and activators of the transcription 3 (STAT3) pathway (20). Although previous studies have suggested that the expression and activation of c-Met may play important roles in the growth of HCC cells, and especially those induced by DCP, c-Met inhibitor has never been analyzed in terms of the suppression of HCC cell growth activated by DCP.

The aim of the present study was to clarify the inhibitory effect that a small-molecular inhibitor of c-Met had on HCC cell growth and its relationship to DCP.

2. Materials and Methods

2.1. Compound

A small-molecular c-Met inhibitor named SU11274 ((3Z)-*N*-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl}methylene)-*N*-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide, Mol. Wt. = 568.09) was purchased from Calbiochem, Inc. (San Diego, CA, USA) (21). This compound was dissolved in dimethyl sulfoxide (DMSO) solution so that the concentration of DMSO was less than 0.1% (v/v) in the analyzed samples.

DCP was generously donated by Eisai Co., Ltd., Tokyo, Japan. DCP was purified from the conditioned media of the DCP-producing cell line PLC/PRF/5 by affinity chromatography with an anti-prothrombin antibody. DCP was distinguished from normal prothrombin using high-performance liquid chromatography (HPLC) (20).

2.2. Cell lines

HepG₂ (a well-differentiated HCC cell line) cells were obtained from European Collection of Animal Cell Cultures (ECACC, Salisbury, UK). HuH-7 (a well-differentiated HCC cell line) and HLE (poorly-differentiated HCC cell line) cells were obtained from Health Science Research Resources Bank (HSRRB, Osaka, Japan). These cells were maintained in Dulbecco's modified Eagle's Medium (DMEM) with 10% fetal bovine serum (FBS) at 37°C in a humid atmosphere (5% CO₂-95% air) and were harvested by brief incubation in Enzyme-free Cell Dissociation Solution (Millipore Co., Bedford, MA, USA).

2.3. Cell growth assay

Continuously cultured HepG₂, HuH-7 and HLE cells were harvested in tubes and resuspended in DMEM containing 10% FBS after they were washed with PBS. The cells were seeded in triplicate in 96-well plates at a density of 6×10^3 cells in 100 μ L with or without a concentration of SU11274 and/or DCP and incubated for 24 and 72 h at 37°C in a 5% CO₂ atmosphere. Cell viability was evaluated using a methylthiazole tetrazolium (MTT) cell proliferation assay kit in accordance with the manufacturer's instructions (Roche Diagnostics, Basel, Switzerland). The IC₅₀ (concentration of drug that inhibits cell growth by 50%) value was calculated using SPSS 11.5 software.

2.4. Western blot analysis

Continuously cultured HepG₂, HuH-7 and HLE cells were harvested in tubes and resuspended in DMEM containing 10% FBS after they were washed with PBS. The cells were seeded in triplicate in 6-well plates at a density of 3×10^5 cells in 2 mL with or without a concentration of SU11274 and incubated for 48 h at 37°C in a 5% CO₂ atmosphere. Then, the cells were harvested in tubes and total cell lysates were prepared as previously described (22). Protein concentrations of supernatant were determined using the DC Protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Thirty μ g of total cellular proteins were resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride (PVDF) transfer membranes by Western blotting. Rabbit anti-human c-Met polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-human phosphorylated-c-Met polyclonal antibody (Cell Signaling Technology, Danvers, MA, USA), rabbit anti-human phosphorylated-extracellular signal-regulated kinase (ERK) polyclonal antibody (Cell Signaling Technology, Danvers, MA, USA), and mouse anti-human β -actin monoclonal antibody (Sigma-Aldrich, St. Louis, MO, USA) were used as primary antibodies.

2.5. Statistical analysis

Statistical analysis was performed with the Student's *t*-test using SPSS 11.5 software. $p < 0.05$ was indicative of a significant difference. All experiments were performed in triplicate.

3. Results and Discussion

First, the inhibitory effect of c-Met inhibitor SU11274 on HCC cell growth was analyzed. As shown in Figure 1, the growth of all HCC cell lines analyzed was inhibited by the addition of SU11274. This inhibitory

effect was particularly apparent with over 2.5 μM of SU11274. This inhibitory effect occurred in a time- and dose-dependent manner but differed among HCC cell lines with 48 and 72 h of incubation. The growth of HLE cells was gradually inhibited by a lower concentration of SU11274 (0.0625-1.25 μM) although those concentrations of SU11274 had no significant effect on the growth of HepG₂ and HuH-7. However, similar IC₅₀ values were noted for the cell lines analyzed; 8.16 μM SU11274 and 48 h of incubation and 6.75 μM SU11274 and 72 h of incubation inhibited HepG₂ cells, 8.24 μM SU11274 and 48 h of incubation and 8.08 μM SU11274 and 72 h of incubation inhibited HuH-7 cells, and 6.36 μM SU11274 and 48 h of incubation and 7.20 μM SU11274 and 72 h of incubation inhibited HLE cells. These results suggest that the addition of the small-molecular c-Met inhibitor SU11274 may inhibit the growth of HCC cells.

Next, Western blot analysis was performed to clarify

the changes in c-Met expression or its activation profile as a result of SU11274. All HCC cell lines analyzed were positive for c-Met expression, and this level of expression in those HCC cell lines did not change significantly with the addition of SU11274 (Figure 2). In contrast, the expression of phosphorylated-c-Met gradually decreased in a dose-dependent manner with SU11274. The rate of inhibited expression of phosphorylated-c-Met in the presence of 5 μM SU11274 was 43%, 84%, and 53% for HepG₂, HuH-7, and HLE cells, respectively. In addition, the expression of phosphorylated-ERK, the downstream kinase of the signal transduction pathway activated by c-Met, also decreased in a dose-dependent manner with SU11274. The rate of inhibited expression of phosphorylated-ERK in the presence of 5 μM SU11274 was 18%, 39%, and 78% for HepG₂, HuH-7, and HLE cells, respectively. These results suggest that the down-regulation of c-Met activation by SU11274 may inhibit the growth of HCC cells.

As described previously, c-Met may act as a target receptor of DCP and trigger the activation of HCC cell growth (20). Therefore, the inhibition of c-Met presumably suppresses HCC cell growth induced by DCP. The present study investigated the ability of SU11274 to inhibit DCP by simultaneously




Figure 1. Relative growth rates of (A) HepG₂, (B) HuH-7 and (C) HLE cells in the various concentrations of SU11274. White column, 24 h; gray column, 48 h; solid column, 72 h incubation with SU11274. The data represent mean \pm S.D. * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$ vs. control with 0 μM SU11274.




Figure 2. Expressed levels of phosphorylated-c-Met, overall c-Met, and phosphorylated-ERK in (A) HepG₂, (B) HuH-7 and (C) HLE cells detected by Western blot analysis.




Figure 3. Relative growth rates of (A) HepG₂, (B) HuH-7 and (C) HLE cells in the presence of DCP (160 ng/mL) and/or SU11274 (2.5 μ M). Whereas the growth of HCC cells was activated by the addition of DCP, the presence of SU11274 with DCP significantly inhibited this action. The data represent mean \pm S.D. ($n = 3$). * $p < 0.05$ vs. sample with DCP.

incubating HCC cells with these substances for 48 h. The concentration of DCP was set at 160 ng/mL in accordance with the results of a previous study (19). In addition, the concentration of SU11274 was set at 2.5 μ M because the inhibitory effect on cell growth was detected with 5 μ M and 48 h of incubation (Figure 1). As a result, the incubation of HCC cells with DCP activated HCC cell growth, as shown in Figure 3. Previous studies also analyzed the effect of DCP on HCC cell growth using HepG₂ (19) and results of those studies coincided with the results of the present study. The results indicated that the relative extent of growth in the presence of DCP differed among the HCC cell lines analyzed, and this difference may be due to their sensitivity to DCP. The effect of SU11274 on DCP was also analyzed. The activation of HCC cell growth by DCP was neutralized by the simultaneous addition of SU11274 (Figure 3). These results indicate that the

growth of HCC cells was up-regulated by DCP via the activation of c-Met and that these biological events can be inhibited by c-Met inhibitor.

This study was performed with the aim of evaluating the effectiveness of the c-Met inhibitor SU11274 as an anti-cancer chemotherapeutic agent in treating HCC cells. Results revealed that SU11274 had the ability to inhibit HCC cell growth. Several mechanisms whereby the activation of c-Met leads to HCC progression have been suggested. These mechanisms involve ERK-mediated and phosphatidylinositol 3 kinase (PI3K)-mediated pathways (23). As described previously, the JAK-STAT3 pathway may also play an important role in the up-regulation of HCC cell proliferation induced by DCP (20). Thus, various pathways triggered by activated c-Met might regulate the behavior of HCC. Further clarification of the c-Met-mediated mechanism of HCC progression may lead to the development of novel chemotherapeutic agents for HCC.

In conclusion, this study reported that inhibition of c-Met by the small-molecular inhibitor SU11274 arrested HCC cell growth. In addition, DCP's action as a growth factor might be neutralized by the inhibition of c-Met activation. Various researchers are developing novel c-Met inhibitors (24,25), and these inhibitors may prove of use in chemotherapy to treat HCC.

Acknowledgements

This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS).

References

- Di Renzo MF, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, Gaglia P, Zara P, Comoglio PM. Expression of the Met/HGF receptor in normal and neoplastic human tissues. *Oncogene*. 1991; 6:1997-2003.
- Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. *Nature*. 1989; 342:440-443.
- Gohda E, Tsubouchi H, Nakayama H, Hirono S, Sakiyama O, Takahashi K, Miyazaki H, Hashimoto S, Daikuhara Y. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. *J Clin Invest*. 1988; 81:414-419.
- Lee KH, Choi EY, Hyun MS, Eun JR, Jang BI, Kim TN, Lee HJ, Lee DS, Yun SS, Kim HJ, Kim JH, Kim JR. Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma. *Tumori*. 2008; 94:523-530.
- Kondo A, Hirayama N, Sugito Y, Shono M, Tanaka T, Kitamura N. Coupling of Grb2 to Gab1 mediates hepatocyte growth factor-induced high intensity ERK signal required for inhibition of HepG₂ hepatoma cell proliferation. *J Biol Chem*. 2008; 283:1428-1436.

6. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. *Oncogene*. 2010; 29:4989-5005.
7. Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y, Ito T, Katayama K, Sasaki Y, Ito A, Kisida Y, Kashiwagi T, Fusamoto H, Kamada T. Expression of the c-met protooncogene in human hepatocellular carcinoma. *Hepatology*. 1994; 20:1231-1236.
8. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. *Hepatology*. 1997; 25:619-623.
9. D'Errico A, Fiorentino M, Ponzetto A, Daikuhara Y, Tsubouchi H, Brechot C, Scoazec JY, Grigioni WF. Liver hepatocyte growth factor does not always correlate with hepatocellular proliferation in human liver lesions: Its specific receptor c-met does. *Hepatology*. 1996; 24:60-64.
10. Zhang SZ, Pan FY, Xu JF, Yuan J, Guo SY, Dai G, Xue B, Shen WG, Wen CJ, Zhao DH, Li CJ. Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth *in vitro* and *in vivo*. *Mol Cancer Ther*. 2005; 4:1577-1584.
11. Xie B, Xing R, Chen P, Gou Y, Li S, Xiao J, Dong J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. *J Surg Res*. 2010; 162:231-238.
12. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma-carboxy prothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. *Hepatology*. 2003; 37:1114-1121.
13. Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY. Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. *World J Gastroenterol*. 2005; 11:6115-6119.
14. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: A prospective study. *Hepatogastroenterology*. 2002; 49:235-238.
15. Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. *Oncology*. 2007; 72:52-57.
16. Inagaki Y, Tang W, Xu H, Wang F, Nakata M, Sugawara Y, Kokudo N. Des-gamma-carboxy prothrombin: Clinical effectiveness and biochemical importance. *Biosci Trends*. 2008; 2:53-60.
17. Toyoda H, Kumada T, Kiriya S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. *Clin Gastroenterol Hepatol*. 2006; 4:111-117.
18. Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. *Ann Surg Oncol*. 2009; 16:2795-2804.
19. Gao FJ, Cui SX, Chen MH, Cheng YN, Sun LR, Ward SG, Kokudo N, Tang W, Qu XJ. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. *Life Sci*. 2008; 83:815-820.
20. Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y, Koike K, Takaki A, Shiratori Y. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. *J Biol Chem*. 2005; 280:6409-6415.
21. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. *Cancer Res*. 2003; 63:5462-5469.
22. Qi FH, Li AY, Lv H, Zhao L, Li JJ, Gao B, Tang W. Apoptosis-inducing effect of cinobufacini, Bufo bufo gargarizans Cantor skin extract, on human hepatoma cell line BEL-7402. *Drug Discov Ther*. 2008; 2:339-343.
23. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. *Cancer Lett*. 2005; 225:1-26.
24. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. *Mol Cancer Ther*. 2010; 9:1544-1553.
25. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M, Obaishi H. E7050: A dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. *Cancer Sci*. 2010; 101:210-215.

(Received February 5, 2011; Revised April 8, 2011; Accepted April 15, 2011)

Basiliximab as therapy for acute rejection after liver transplantation for hepatitis C virus cirrhosis

Junichi Togashi¹, Yasuhiko Sugawara^{1,*}, Sumihito Tamura¹, Junichi Kaneko¹, Noriyo Yamashiki², Taku Aoki¹, Kiyoshi Hasegawa¹, Norihiro Kokudo¹

¹Artificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;

²Organ Transplantation Service, The University of Tokyo Hospital, Tokyo, Japan.

Summary

Steroid bolus therapy for acute rejection after liver transplantation for hepatitis C virus (HCV) cirrhosis often results in graft loss due to adverse effects. The efficacy and safety of basiliximab for the treatment of acute cellular rejection (ACR) in adult liver transplantation has not been adequately evaluated. Three patients received basiliximab as rescue therapy for acute rejection. The outcome and biochemical parameters were recorded before and after treatment with basiliximab. These results were compared to 11 patients who received steroid therapy for ACR. The median time from transplantation to the development of ACR was 19 days (range, 9-49 days). The degree of ACR was mild or moderate. Resolution of rejection was obtained in all patients and the median time from the onset to resolution of ACR was 16 days (range, 6-41 days). A steroid resistant reaction occurred in 2 of 11 patients and OKT3 was used, and the rejection eventually resolved in all patients. Five patients died within 2 to 22 months after transplantation and four of them died from graft failure. In the basiliximab group, there were no significant immediate adverse effects. One patient died from pneumonia 8 months after transplantation. In conclusion: Basiliximab can be safely used as rescue therapy for ACR without significant adverse effects in patients who underwent liver transplantation for HCV cirrhosis.

Keywords: Hepatitis C, donor, living donor liver transplantation

1. Introduction

Liver transplantation is an effective treatment for end-stage liver disease due to hepatitis C virus (HCV). Despite major advances in immunosuppression, acute cellular rejection (ACR) remains a significant postoperative issue. This can be a major risk factor for the development of chronic allograft rejection and graft loss. Despite the use of calcineurin inhibitors, ACR occurs in 36% to 57% of transplant recipients (1). Typical management involves optimization of baseline immunosuppression and methylprednisolone

boluses. In addition, 28% to 35% (2) of patients do not respond to high-dose steroid therapy and require further intervention, including antithymocyte globulin or OKT3. Repeated high-dose steroids and OKT3, however, reduce graft survival as a consequence of severe HCV recurrence (3).

Basiliximab is a chimeric (human/mouse) monoclonal antibody that selectively binds to the α subunit (CD25) of the interleukin-2 (IL-2) receptor (4), preventing normal T-cell proliferation and thereby the progression of ACR (5). IL-2 promotes the proliferation of activated T cells by engaging the IL-2 receptor, and this has a crucial role in the mediation of ACR. The efficacy of basiliximab has been evaluated and has been shown to rescue the graft from ACR (6). In the present study, we examined the efficacy and safety of basiliximab as a therapeutic agent for rescue of ACR in liver recipients for HCV-related cirrhosis, in comparison with conventional high-dose steroid therapy.

*Address correspondence to:

Yasuhiko Sugawara, Artificial Organ and Transplantation Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
e-mail: yasusuga-tyk@umin.ac.jp

2. Patients and Methods

We performed 213 adult liver transplantations from 2004 to September 2010. Of these, 89 were transplanted due to HCV cirrhosis (4 patients co-infected with HIV were excluded). Of the 89 patients, 16 (18%) were complicated with ACR within 60 days after transplantation at the University of Tokyo Hospital. The ACR rate in the patients other than HCV during the same period was 29% ($n = 294$) which was higher than that of HCV patients without significant difference. After transplantation, all of the patients received the same immunosuppressive treatment with tacrolimus and methylprednisolone, as described previously (7). Briefly, target tacrolimus trough levels were 15 to 20 ng/mL during the first 2 weeks and 10 to 15 ng/mL thereafter. Intravenous methylprednisolone was started during the operation (20 mg/kg/day), and gradually tapered thereafter (7 days after transplantation, 0.75 mg/kg; two weeks, 0.35 mg/kg; one month, 0.3 mg/kg; two months, 0.25 mg/kg; three months, 0.2 mg/kg; 4 months, 0.2 mg/kg). The subjects comprised 12 men and 4 women who underwent liver transplantation with subsequent development of ACR. ACR was defined as a biopsy-proven episode and graded according to the Banff schema (8). The indication for liver biopsy was a significant increase in total bilirubin, aspartate, and alanine aminotransferase levels.

Until the end of 2007, the patients were treated with bolus intravenous methylprednisolone, regardless of ACR severity, at a starting dose of 20 mg/kg/day, as previously described (9). The dose was reduced by half each day and the therapy was continued for 5 days. When acute rejection was refractory to high-dose methylprednisolone therapy, a second bolus was then given with mycophenolate mofetil (CellCept, Roche Pharmaceuticals, Basel, Switzerland; 3 g/day). If the rejection was not cured by two rounds of steroid therapy the episode was diagnosed as steroid-resistant

rejection and OKT3 was administered (Figure 1). After 2008, the regimen was changed. Basiliximab (two 20-mg doses with a 2-day inter-dose interval; Simulect, Novartis Pharmaceuticals, Basel, Switzerland) was added to the immunosuppressive treatment with tacrolimus and methylprednisolone. No bolus intravenous methylprednisolone was administered. The primary outcome measures were treatment success with resolution of ACR, as indicated by normalization of alanine aminotransferase or resolution of liver biopsy changes, or treatment failure due to ongoing rejection. No infectious prophylaxis was done. Immediate treatment of adverse effects and infectious complications within 1 month of treatment were recorded.

3. Results and Discussion

The median time from transplantation to the development of ACR was 19 days (range, 9-49 days). The degree of ACR was mild or moderate. Median follow-up from transplantation was 25 months (range, 2-81 months).

Treatment outcomes are summarized in Table 1. Of the 11 patients in the steroid group, 2 had a steroid-resistant reaction and OKT3 was used. The overall rejection grade in the two patients was moderate. In a semi quantitative assessment, venous endothelial inflammation was scored as 2 (moderate). Rejection eventually resolved in all patients, which was confirmed by the subsequent biopsy in 7. Five patients died within 2 to 22 months after transplantation and four of them died from graft failure. In all three patients in the basiliximab group, rejection resolved without significant immediate adverse effects. In one patient the resolution was histologically confirmed (Banff rejection activity index changed from 4 to 2 after the therapy). One patient died of pneumonia 8 months after transplantation.

Aspartate aminotransferase levels normalized in all patients. The median time from the onset to resolution of ACR was 16 days (range, 6-41 days).

The present report confirms that basiliximab can be effective in reversing ACR in HCV patients. All patients with histologic evidence of ACR before treatment with basiliximab had resolution of ACR. Three patients with ACR were managed effectively with basiliximab without the addition of other immunosuppressive agents. Furthermore, none of these patients had recurrent episodes of ACR. In contrast, of the 11 patients complicated with ACR that received steroid pulse therapy, 4 died of graft failure, probably due to HCV recurrence, although ACR was successfully resolved in all cases.

The safety of basiliximab was previously reported, with no evidence of significant acute toxicity (2,10) or increased risk of infection (11). There have been




Figure 1. Regimens in the steroid and basiliximab groups. Abbreviations: FK, tacrolimus; MMF, mycophenolate mofetil.

Table 1. Patients and treatment outcomes

Age, sex	ACR onset (d)	On the day ACR diagnosis		Number of steroid boluses	MMF	OKT	Interval for ACR resolution (d)	After the therapy		Outcome	Cause of death
		Banff score	Blood test (ALT/ALP/TB)					Banff score	Blood test (ALT/ALP/TB)		
Steroid group											
44, M	42	3	314/546/0.7	1	No	No	23	–	36/471/1.2	81A	–
57, M	11	4	86/521/1.3	3	Yes	No	39	2	28/338/0.8	81A	–
57, M	39	3	58/752/0.7	1	No	No	26	–	30/461/0.5	80A	–
48, F	34	5	315/180/1.1	3	Yes	Yes	8	2	30/121/2.6	3D	Graft failure
63, M	18	4	89/318/0.8	1	No	No	10	–	33/218/0.6	73A	–
45, M	30	5	192/143/2.9	2	Yes	Yes	12	1	44/180/3.6	22D	Graft failure
49, M	16	3	185/269/1.9	2	Yes	No	40	1	30/258/3.1	3D	Graft failure
47, M	9	3	44/134/1.4	1	No	No	12	–	14/118/0.7	58A	–
47, M	9	3	45/229/14.5	2	Yes	No	41	1	34/470/9.2	2D	Graft failure
49, M	12	4	127/288/0.9	1	No	No	17	1	35/225/0.5	50A	–
58, F	19	3	45/469/4.5	1	No	No	38	1	35/431/3.1	9D	TMA
Basiliximab group											
55, M	44	3	125/888/0.5	0	No	No	7	–	14/432/0.5	27A	–
61, F	49	4	112/1077/2.1	0	Yes	No	15	2	48/653/1.6	8D	Pneumonia
60, F	19	3	100/448/3.5	0	No	No	6	–	36/265/2.2	3A	–

Abbreviations: ACR, acute cellular rejection; A, alive; D, dead; TMA, thrombomicroangiopathy; MMF, mycophenolate mofetil; ALT/ALP/TB, alanine aminotransferase (IU/L)/alkaline phosphatase (IU/L)/total bilirubin (md/dL).

several reports of cytomegalovirus viremia after induction with anti-IL-2 receptor antibodies, but to date there is no evidence of a significant increased risk of cytomegalovirus infection (12). In this series, one patient died of pneumonia 8 months after liver transplantation, which may not be directly attributable to basiliximab therapy.

HCV recurrence developed in most HCV-positive recipients. The intensity of immunosuppression correlates with recurrent HCV hepatitis after transplantation (13). Importantly, Kato *et al.* (14) reported that tacrolimus along with daclizumab and a steroid-free regimen resulted in fewer HCV infection recurrences after transplantation. The use of basiliximab therefore seems to be advantageous over steroid therapy in HCV-positive patients.

Our results are comparable to those of other case series in which basiliximab was used as rescue therapy. Orr *et al.* (15) used basiliximab in 16 patients with steroid-resistant ACR, and resolution was achieved in 12 (75%) cases. Similarly, in another study (16), 5 (71.4%) of 7 liver transplant recipients with steroid-resistant ACR were successfully treated with basiliximab. Another series (6) showed resolution of ACR in adult renal and liver recipients, 72% of whom were successfully treated with basiliximab. The findings of that study (6) suggest that the efficacy of anti-IL-2 receptor antibody in ACR is similar to that of high-dose steroids, although there are no prospective randomized trials that have tested this hypothesis.

Anti-IL-2 receptor antibodies are now widely used in liver transplantation as induction agents targeted at reducing the incidence of ACR (2,17,18) or as a calcineurin-inhibitor (19) or steroid-sparing strategy (20,21) to protect renal function in the immediate postoperative period. Comparison of induction therapy (12) between antithymocyte globulin + cyclosporine + steroid + azathioprine and anti-IL-2 receptor antibody

+ tacrolimus + steroid + azathioprine demonstrated a reduced ACR incidence in the anti-IL-2 receptor antibody group (43% versus 29%; $p < 0.01$). Patients treated with anti-IL-2 receptor antibodies also had fewer infective complications. The results of a meta-analysis of treatment with anti-IL-2 receptor antibodies in renal transplantation (22) confirmed that the risk for ACR was reduced by 49% at 6 months. Importantly, however, their use did not significantly reduce graft loss or mortality at 1 year. Prospective randomized studies comparing calcineurin inhibitors + steroid + basiliximab and calcineurin inhibitors + steroid showed a lower (23) or similar (24,25) ACR rate and no difference in graft survival.

A limitation of this study is that it was a retrospective and nonrandomized case series. The small number of patients enrolled in the study was insufficient to yield statistically meaningful results. These preliminary data, however, indicate that the use of anti-IL-2 receptor antibodies is safe for the treatment of ACR in HCV-positive patients. Prospective studies are now needed to evaluate the use of anti-IL-2 receptor antibodies as a first-line therapy for ACR for HCV-positive patients.

Acknowledgements

This project was supported by a grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, and Science of Japan.

References

- Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB. Immunosuppression: Evolution in practice and trends, 1993-2003. *Am J Transplant.* 2005; 5:874-886.
- Nashan B, Schlitt HJ, Schwitzer R, Ringe B, Kuse E,

- Tusch G, Wonigeit K, Pichlmayr R. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. *Transplantation*. 1996; 61:546-554.
3. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. *Transplantation*. 2004; 77:226-231.
 4. Ramirez CB, Marino IR. The role of basiliximab induction therapy in organ transplantation. *Expert Opin Biol Ther*. 2007; 7:137-148.
 5. Nikaido T, Shimizu A, Ishida N, Sabe H, Teshigawara K, Maeda M, Uchiyama T, Yodoi J, Honjo T. Molecular cloning of cDNA encoding human interleukin-2 receptor. *Nature*. 1984; 311:631-635.
 6. Chariat MN, Erren M, Chariat M, Deng M, Wolters HH, Dietl KH. Basiliximab in the therapy of acute rejection after organ transplantation. *Transplant Proc*. 2001; 33:2380.
 7. Sugawara Y, Mizuta K, Kawarasaki H, Takayama T, Imamura H, Makuuchi M. Risk factors for acute rejection in pediatric living related liver transplantation: The impact of HLA matching. *Liver Transpl*. 2001; 7:769-773.
 8. Terminology for hepatic allograft rejection. International Working Party. *Hepatology*. 1995; 22:648-654.
 9. Sugawara Y, Tamura S, Kaneko J, Togashi J, Makuuchi M, Kokudo N. Positive lymphocytotoxic crossmatch does not adversely affect survival in living donor liver transplantation. *Dig Surg*. 2009; 26:482-486.
 10. Friend PJ, Waldmann H, Cobbold S, *et al*. The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. *Transplant Proc*. 1991; 23:1390-1392.
 11. Raakow R, Steffen R, Knoop M, Blumhardt G, Lemmens P, Wiens M, Keck H, Neuhaus P. Quadruple immunosuppression including a new IL-2-receptor antibody and the incidence of infections after liver transplantation. *Transpl Int*. 1992; 5:S168-S169.
 12. Langrehr JM, Schneller A, Guckelberger O, Lohmann R, Neumann U, Jonas S, Klupp J, Settmacher U, Knoop M, Bechstein WO, Neuhaus PJ. Comparison of quadruple induction including ATG or IL-2R antibody with FK506-based therapy after liver transplantation. *Transplant Proc*. 1998; 30:1439-1440.
 13. Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C, Morelli F, Laskus T, Fung JJ, Rakela J, Starzl TE. Hepatitis C virus genotypes in liver transplant recipients: Impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. *Transplantation*. 1997; 64:422-426.
 14. Kato T, Gaynor JJ, Yoshida H, Montalvano M, Takahashi H, Pysopoulos N, Nishida S, Moon J, Selvaggi G, Levi D, Ruiz P, Schiff E, Tzakis A. Randomized trial of steroid-free induction *versus* corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: Impact on hepatic fibrosis progression at one year. *Transplantation*. 2007; 84:829-835.
 15. Orr DW, Portmann BC, Knisely AS, Stoll S, Rela M, Muiesan P, Bowles MJ, Heaton ND, O'Grady JG, Heneghan MA. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. *Transplant Proc*. 2005; 37:4373-4379.
 16. Aw MM, Taylor RM, Verma A, Parke A, Baker AJ, Hadzic D, Muiesan P, Rela M, Heaton ND, Mieli-Vergani G, Dhawan A. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transplant recipients: A preliminary experience. *Transplantation*. 2003; 75:796-799.
 17. Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. *J Surg Res*. 2007; 138:198-204.
 18. Gruttadauria S, Mandala L, Biondo D, Spampinato M, Lamonaca V, Volpes R, Vizzini G, Marsh J, Marcos A, Gridelli B. Role of basiliximab in the prevention of acute cellular rejection in adult to adult living-related liver transplantation: A single center experience. *Biologics*. 2007; 1:69-73.
 19. Lin CC, Chuang FR, Lee CH, Wang CC, Chen YS, Liu YW, Jawan B, Chen CL. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. *Liver Transpl*. 2005; 11:1258-1264.
 20. Lladó L, Xiol X, Figueras J, Ramos E, Memba R, Serrano T, Torras J, Garcia-Gil A, Gonzalez-Pinto I, Castellote J, Baliellas C, Fabregat J, Rafecas A; Thosin Study Group. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: Results from a prospective multicenter randomized study. *J Hepatol*. 2006; 44:710-716.
 21. Gras JM, Gerkens S, Beguin C, Janssen M, Smets F, Otte JB, Sokal E, Reding R. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: Clinical and pharmacoeconomic study in 50 children. *Liver Transpl*. 2008; 14:469-477.
 22. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. *BMJ*. 2003; 326:789.
 23. Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortman E, Chodoff L, Hall M, Korn A, Nashan B. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results from a double-blind randomized placebo-controlled trial. *Liver Transpl*. 2002; 8:132-142.
 24. Lupo L, Panzera P, Tandoi F, Carbotta G, Giannelli G, Santantonio T, Rendina M, Gentile A, Memeo V. Basiliximab *versus* steroids in double therapy immunosuppression in liver transplantation: A prospective randomized clinical trial. *Transplantation*. 2008; 86:925-931.
 25. Schmeding M, Sauer IM, Kiessling A, Pratschke J, Neuhaus R, Neuhaus P, Neumann UP. Influence of basiliximab induction therapy on long term outcome after liver transplantation, a prospectively randomised trial. *Ann Transplant*. 2007; 12:15-21.

(Received March 24, 2011; Revised April 15, 2011; Accepted April 16, 2011)

Content analysis of school textbooks on health topics: A systematic review

Marino Nomoto^{1,*}, Daisuke Nonaka², Tetsuya Mizoue², Jun Kobayashi³, Masamine Jimba¹

¹Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;

²Department of Epidemiology and International Health, National Center for Global Health and Medicine, Tokyo, Japan;

³Bureau of International Medical Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.

Summary

High-quality textbooks and learning materials are especially important for school children, but school textbooks may contain incorrect health information. The objective of this study was to review the findings of analytical studies about the contents of textbooks used in elementary, junior high, or high schools. Of 450 studies we screened, we reviewed 14 that met the inclusion criteria, and summarized information regarding: *i*) authors and publication year, *ii*) target country, *iii*) topics selected, *iv*) school level, *v*) textbook subject(s), *vi*) analytical methods, and *vii*) findings. Of the selected 14 studies, 9 were conducted in the United States and Spain. Health topics focused mainly on sexuality, HIV/AIDS, and nutrition. The reviewed studies were classified according to the amount of topic information they contained, the accuracy of the health information provided, and the health information priorities conveyed. The findings of reviewed studies can be summarized as follows: some current school textbooks provide insufficient content and contain inaccurate or out-of-date health information. This study found through health-related content analysis of the school textbooks that textbooks in the United States and Spain cover sexuality, sexually transmitted diseases, and nutrition more often than do textbooks in other countries. Content quality is sometimes inappropriate and requires improvement.

Keywords: School textbooks, school health, health education, content analysis, systematic review

1. Introduction

School health education has proven to be effective in increasing knowledge and improving attitudes, beliefs, and skills needed to practice healthy behaviors (1,2). School textbooks are essential materials for school health education (3,4). Particularly in resource-limited settings, school textbooks can play an important role as a source of reliable information (5). Because school textbooks can provide health information on disease prevention and essential health skills, the information

they contain must be reliable. The United Nations Educational, Scientific and Cultural Organization (UNESCO) emphasizes improving the quality of textbooks as one of its policy recommendations within the Education For All Framework (6).

Despite the importance of accuracy, however, previous studies have indicated that school textbooks contain incorrect or insufficient health information (7). To reduce the likelihood of students receiving and accepting incorrect information, regular revision and regular improvement of content quality is essential for raising the health levels of students and their family members. Reviews of school textbooks by government authorities and the inclusion of priorities of national health policies are also recommended, yet few studies have assessed textbooks in terms of their health information content or examined their accuracy and frequency of revision.

*Address correspondence to:

Dr. Marino Nomoto, Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.

e-mail: marino13@m.u-tokyo.ac.jp

The objective of this study was to review the findings of analytical studies of the contents of textbooks used in elementary, junior high, and high schools.

2. Methods

2.1. Search strategy and inclusion/exclusion criteria

We did a search for eligible literature regarding school health and school textbooks. First, we conducted an electronic search of popular academic databases for health and education. Our electronic search strategy was first to look at the PubMed and the Education Resources Information Center (ERIC) Internet databases. PubMed is a service of the U.S. National Library of Medicine from MEDLINE and other life science journals of a biomedical nature. ERIC is an online digital library of education research and information, sponsored by the Institute of Education Sciences of the U.S. Department of Education. Both databases seemed appropriate choices because they are widely used in their respective fields (medicine and education) and cover the key words of the reviewed studies. In both PubMed and ERIC, the key words "schools" AND "textbooks" AND "health" were used

to retrieve articles published between January 1980 and June 2009, with no language restrictions. The search strategy also included a review of the references cited by the identified studies. The process and the number of systematic reviews are shown in Figure 1.

The inclusion criteria were the following: the study must include content analysis of school textbooks; the textbooks examined must be used in elementary, junior high, or high school; the textbooks must include health-related information; and the articles must have been published between 1980 and 2009. As education systems in different countries differ, school levels were classified according to grades or ages, and defined as elementary school, junior high school, or high school. Content analysis is defined as the systematic, objective, qualitative analysis of message characteristics (8). Exclusion criteria were content analysis of content unrelated to health, use of intervention analysis, or use of the textbooks in kindergartens or college/university-level education.

Titles and abstracts of studies were screened primarily using the key words. Two reviewers independently assessed all titles and abstracts retrieved through the electronic searches. An initial relevance screening generated 450 studies in total from the literature search, including 245 studies from PubMed




Figure 1. Flow chart of the study selection process. ^a The 383 excluded articles included those with no content analysis or content analysis on other topics. ^b These 25 articles were excluded because target school levels did not meet the inclusion criteria. ^c These 28 excluded articles included intervention studies or content analysis not related to health topics.

and 205 from ERIC.

Of these 450 studies, 383 were excluded due to a lack of content analysis or a suggestion in the titles or abstracts that the content analysis was of non-health-related content. This screening yielded 67 studies that met the initial inclusion criteria. Next, the abstracts of the 67 studies were collected and independently reviewed, and excluded from full-text review if the content analysis was not focused on school textbooks or if the topic was not health-related.

Of the 67 studies, 25 were excluded because their target school levels did not meet our inclusion criteria. The remaining 42 studies returned by the searches were included in the full-text review. Full-text copies of the 42 studies identified as potentially relevant were retrieved; their full texts in English were collected and reviewed; they included 8 non-English studies that had been translated into English. In cases where reviewers disagreed on the eligibility of reviews, a discussion was held in order to obtain consensus. The studies in full-text were included if they met all of the above-mentioned inclusion criteria (use of content analysis, use of textbooks in elementary, junior high, or high school, and focus on health information, including hygiene, infectious diseases, and other health topics). We excluded intervention studies and systematic reviews. The 42 full-text screened studies were reexamined several times by two reviewers.

Of the 42 full-text studies, 28 were excluded because they included intervention studies or systematic reviews, or they analyzed non-health content. Ultimately 14 studies met the inclusion criteria and were examined. Of the 14 studies, 5 were not written in English: 3 were in Spanish (4,9,10), 1 was in Portuguese (11), and 1 was in German (12). We asked native speakers of Spanish, Portuguese, and German to translate the 5 studies into English and reviewed the English translations. Searches were conducted between May and August 2009.

2.2. Assessment

All the studies of content analysis were examined from two aspects: the content of relevant domains, and the total numbers of pages, tables, figures, and pictures/illustrations. All were summarized using a form containing 7 categories for comparison. The 7 categories included: *i*) authors of references and year of publication, *ii*) target country, *iii*) specific health topic, *iv*) school level or grade, *v*) textbook subject(s), *vi*) analytical method(s), and *vii*) findings. This process resulted in a document with tables.

3. Results

We summarized the characteristics of the 14 studies of content analysis we examined in Table 1.

3.1. Target country

Of 14 studies, 12 were conducted in North America or Europe. The target countries were: the United States in 6 studies, Spain in 3, and Brazil, Canada, Mexico, Switzerland, and the United Kingdom in 1 each. Twelve of the studies were conducted in developed countries, 2 in middle-income countries, none in low-income countries.

3.2. Specific health topics covered

Of the 14 studies, 2 evaluated the priorities of the health information content in the textbooks (4,9). The main health topics in 12 studies were sexuality, sexually transmitted diseases (STDs), and nutrition. Of the included studies, 4 focused on sexuality, including reproductive health, gender representation, and STDs (7,13-15), 3 focused on nutrition or diet, including excessive intake of sugar-rich food (12,16,17), and 1 each focused on HIV/AIDS (10), mental health (18), hearing health (19), oral cancer (20), and vaccination (11). Two other Spanish studies identified the priorities of health topics covered. In a study conducted by Catalán in 2003, the priorities were hygiene, followed by eating (9); in the other study conducted by Barrio Cantalejo *et al.* in 2008, they were diet, physical exercise, and the impact of environmental contamination (4).

3.3. Target school levels and textbook subjects

Target school levels and textbook subjects were diverse. Of the 14 studies, 9 studies targeted a single school level: 5 targeted elementary schools, 3 targeted junior high schools, and 1 targeted high schools. The remaining 5 targeted multiple school levels: 1 study each targeted elementary and junior high schools, elementary and high schools, or junior high and high schools; the remaining 2 studies targeted all three school levels. The textbooks examined covered the full range of subjects: health science, language, arts, mathematics, history, science, arithmetic, algebra, and chemistry.

3.4. Analytical methods

All 14 studies examined were descriptive studies of content analysis. Content analysis is an in-depth analysis of messages using quantitative or qualitative techniques. The studies' analytical methods fell into three main patterns: *i*) analysis of the amount of topic information in words, pictures, and/or illustrations (8 studies); *ii*) examination of the accuracy of health information (2 studies); *iii*) identification of health-related topics and their priorities (2 studies). Of the two remaining studies that did not fall into any of the three main patterns, one identified the impact of political and

Table 1. Results of reviews by target country, school grade level, subjects, and methodology

Author, year	Target country	Specific health topics	School level and grades	Subjects of texts	Analytical methods	Findings
Tolan and Lounsbury, 1982	US	Mental health	High school. No information about grades.	Health textbooks	Examination of community mental health ideology presented in high school health textbooks.	Information in high school health textbooks does not adequately represent modern mental health knowledge or practice. It does not meet society's mental health needs.
D'Onofrio and Singer, 1983	US	Nutrition, sugar, sweets	Grades K-3 in elementary school.	Readers, pre-readers, and reading workbooks	Analysis of food-related content in words and pictures in texts.	Food-related content in the texts revealed an excessive emphasis on sweets in both words and pictures. The poor results of nutrition education have been publically decried. Unintended messages may work against the promotion of healthy eating habits. Textbook revision is clearly indicated.
Kroger and Yarber, 1984	US	STD and sexuality	Junior high school. No information about grades.	Health science and sex education	Assessment of potential contribution of textbooks to STD control objectives.	Sex education textbooks contribute to STD control objectives better than do health science textbooks. Health science textbooks may not contribute toward reducing STD incidence. Both types of textbooks present biomedical information without significant errors.
Frager and Kahn, 1988	US	Hearing health and protection	Elementary school. No information about grades.	School health textbooks	Identification of health information on hearing and assessment of its usefulness to prevent hearing loss.	More content regarding the signs and causes for hearing problems was identified than recommendations for avoiding hearing problems. Hearing health mobilizing information is lacking.
Beyer <i>et al.</i> , 1996	US	Gender representation	Junior high and high school. No information about grades.	History, mathematics, science, and reading	Examination of gender inequity in written textbooks.	Illustrations showed greater female representation. Greater male representation included that related to drug use, sexual exploitation, sexual desire, and homosexuality. Greater female representation included that related to body image, diseases of the reproductive organs, and hygiene.
Baysac <i>et al.</i> , 2004	US	Oral cancer	Grades 1-12 in elementary, junior high, and high school.	Health education	Evaluation of quality, completeness, and accuracy of oral cancer information.	Current school health textbooks do not provide adequate information about oral cancer prevention and early detection. To achieve Healthy People 2010 objectives, correct and adequate information about risk factors and examinations for oral cancer are needed.
Gavdia Catalán, 2003	Spain	All health information	Elementary, junior high, and high school. No information about grades.	All subjects	Identification of 1) presence or absence of education for health, 2) inclusion of health-related topics, 3) degree of health covered, 4) inclusion in the subject or dealt with on a transversal basis, 5) methodological aspects.	Sixty-three percent of the texts analyzed included topics on health education. Most topics were related to hygiene and eating. Health-related concepts most often dealt with are those of being disease-free and in a state of well-being. Current school textbooks are not sufficient either as a point of reference or as an adequate resource.
Barrio Cantalejo <i>et al.</i> , 2008	Spain	All health information	Elementary and high school. No information about grades.	No information about subjects.	Identification of 1) health priorities defined by health organizations, 2) messages on health, 3) extent to which these messages fit the priorities established.	The priorities most frequently covered in the textbooks were diet, physical exercise, and the impact of environmental contamination. The health messages contained in school textbooks are not well adapted to the priorities defined by health organizations.

Abbreviations: STD, sexually transmitted diseases; STI, sexually transmitted infection.

(to be continued)

Table 1. Results of reviews by target country, school grade level, subjects, and methodology (continued)

Author, year	Target country	Specific health topics	School level and grades	Subjects of texts	Analytical methods	Findings
de Irala <i>et al.</i> , 2008	Spain	Sexuality, human reproduction, and STIs	14-15-year-olds in secondary school	Biology	Evaluation of the extent to which textbooks on sexuality and human reproduction promote healthy reproductive lifestyles as well as avoidance of risk behavior among adolescent students.	All textbooks presented inaccurate information and incomplete perception of sexuality or risky behavior. On average, 12.6 incorrect messages were identified in each textbook. Eleven of 12 textbooks examined provided misleading statements on condom use for contraception and STI prevention and on family planning methods. The textbooks were neither appropriate nor sufficiently comprehensive for adolescent education on issues of sexuality. Results suggest a need for alternative textbooks based on better scientific evidence. Teenage sexual activities described in the textbooks are not supported by epidemiological data from the Spanish National Institute of Statistics.
Succi <i>et al.</i> , 2005	Brazil	Vaccines	Grade 1-8 in elementary school	Science and biology	Evaluation of content of textbooks with regard to concepts and information on vaccination.	Despite Ministry of Education recommendations, 34% of elementary-level textbooks did not include the subject of vaccination. More than half of the textbooks with content on vaccines presented some erroneous information on vaccination, errors in vaccination schedules, out-of-date information, omission of content, or inadequate illustrations.
Baron, 1990	Canada	Nutrition	Grade 1-6 in elementary school	Language, arts, and mathematics	Detection of nutrition messages in words and pictures.	A large proportion of references were to sugar-rich foods. Unintended information may influence nutritional habits of children.
Granados-Cosme <i>et al.</i> , 2007	Mexico	HIV/AIDS prevention	Grade 5-6 in elementary and 1-3 grade in junior high school	Natural science, biology, civics, and ethics education	Clarification of social actors' positions and interests and their influence on the content of textbooks.	Those actors whose beliefs are based on tradition and are contrary to modernization oppose the inclusion of topics on sexuality and HIV/AIDS in the school curriculum. The deficiencies and decline in HIV/AIDS prevention education were caused by actions from opposition groups.
Eichholzer-Helbling <i>et al.</i> , 1984	Switzerland	Nutrition	Grade 1-4 in elementary school	Reading, arithmetic, and language	Examination of contents regarding nutrition in the textbooks.	Educational information regarding nutrition can be found in all textbooks, but it was not adjusted to today's perceptions.
Reiss, 1998	UK	Sexuality	14-15-year-olds in high school	Biology and science	Analysis of health topics related to human sexuality in school science textbooks.	Some science textbooks are sensitively written, comprehensive, and helpful. Others fail to tackle personal issues dealing with menstruation, ignore lesbian and gay issues, and either omit or fail to deal adequately with cultural issues in spite of the regulations of the UK Government's own Circular.

Abbreviations: STDs, sexually transmitted diseases; STI, sexually transmitted infection.

social ideology on the content of HIV/AIDS education (10), another identified gender representation and examined gender inequity in textbook descriptions (14).

As the objective basis of analyses, 4 studies cited the country's national health policies or recommendations as a standard, and compared them with the content of health information in the textbooks. The 4 studies cited Healthy People 2010 in the United States, health priorities defined by health organizations or authorities in Spain, or recommendations of the Ministry of Education in Brazil. Other studies had no standards by which to evaluate the contents.

3.5. Findings

To summarize the quality of the school textbooks examined in findings, we chose the amount, the accuracy, and the currency of the health information on target health topics. We showed the results using the "+" symbol in Table 2. Of 14 studies reviewed, 11 reported that the school textbooks examined provided insufficient content or lacked information regarding the target topics; 5 studies reported that the health information in textbooks included inaccuracies or false information; and 5 studies reported that the health information was not current or was out-of-date and needed revision. In total, the authors of 13 of the 14 studies indicated that the textbooks they examined needed further improvement or revision.

In comparisons of the contents with national health policies or priorities, 4 studies cited the target country's health policy or Ministry of Health/Education recommendations as standards. For example, they cited Healthy People 2010 objectives (20), the guidelines of Ministry of Education (MEC) (11), the UK Government's own Circular, the Local

Government Act, and the Education Act (15), 24 priorities defined by the World Health Organization, the European Union, the Spanish Ministry of Health and Consumer Affairs, and the Spanish Society of Public Healthcare Administration (4).

4. Discussion

Content analysis of school textbooks often focused on sexuality/reproductive health and STDs; 4 out of 14 studies focused on these topics. These topics are important because unintended pregnancy is one of the main reasons why female students drop out of school (21,22). Furthermore, young people are particularly vulnerable to HIV infection: 15-24-year-olds account for 50% of new cases worldwide (23). They must be provided with essential skills and information before they become sexually active (24). The authors of these studies examined textbooks used in elementary and junior high schools (targeting 14-15-year-old students).

Although sex education is known to be difficult to deliver in school settings (25), previous studies have reported that school children in many countries identify textbooks or school as their primary source of health information (26-29). The importance of information delivered in school settings has also been demonstrated by its long-term impact on healthy behaviors (30,31). Thus, the contents of school textbooks require regular revision to provide students with accurate health information regarding sexuality, STDs, and reproductive health.

Three studies highlighted the over-representation of graphical information presenting sugar-rich food in the textbooks (12,16,17). The authors suggested the potential impact on school children of the over-representation of unhealthy eating behaviors. As

Table 2. Quality of the school textbooks examined

Author, year	Specific health topics	Quality		
		Insufficient information	Lack accuracy	Out-of-date information/ need revision
Tolan and Lounsbury, 1982	Mental health	+	+	+
D'Onofrio and Singer, 1983	Nutrition		+	
Kroger and Yarber, 1984	STD and sexuality	+		
Fragar and Kahn, 1988	Hearing health and protection	+		+
Beyer <i>et al.</i> , 1996	Gender representation	+		
Baysac <i>et al.</i> , 2004	Oral cancer	+	+	
Gavidia Catalán, 2003	All health topics	+		
Barrio Cantalejo <i>et al.</i> , 2008	All health topics	+		
de Irala <i>et al.</i> , 2008	Sexuality, human reproduction, and STIs	+	+	+
Succi <i>et al.</i> , 2005	Vaccines	+	+	+
Baron, 1990	Nutrition			
Granados-Cosme <i>et al.</i> , 2007	HIV/AIDS prevention	+		
Eichholzer-Helbling <i>et al.</i> , 1984	Nutrition			+
Reiss, 1998	Sexuality	+		

+: include the comment shown at the top of the column.

unintended messages conveyed in textbooks may counteract efforts to promote healthy eating habits, those responsible for textbook selection should draw up health content guidelines.

In the 14 studies we reviewed, none focused on tobacco use, injury prevention, or alcohol/substance abuse, which have been emphasized as central to health education curricula in school settings (32,33). Our results also revealed that the researchers paid little attention to these topics in content analysis. However, educational interventions using various approaches including peer-education and linkage with supportive communities and policies have been intensively utilized in the school setting (34-36). Nonetheless, these studies emphasized the importance of comprehensive approaches and of basic curricula as principal components of health education.

The findings examined by the studies we reviewed were summarized as follows: most of the reviewed articles consistently reported insufficient health information provided by the textbooks. This tendency was particularly evident in the studies dealing with sexuality or STDs (7,13,15). However, 13 out of 14 studies reviewed also reported a wide range of variation among publishers in content insufficiency, inaccuracy, or out-of-date information.

In comparisons of content with national health policies or recommendations, only 4 studies cited the country's national health policy or recommendations as a standard. To evaluate the quality of school textbooks objectively, some standard of comparison is needed.

We also found that studies were mostly confined to developed nations: the target countries of 13 of the 14 studies were the U.S., Spain, Canada, Switzerland or the United Kingdom. This might be due to wider availability of textbooks in developed countries. However, 80% of the world's children live in developing countries where resources for textbook development are more likely to be limited than in developed countries (37,38). School textbooks used in developing countries also need to be examined with a view to improving the contents of health information.

To regularly and reliably provide sufficient and accurate health information in school textbooks to school children, we need to assess the adequacy of all school textbooks, whether they are used in developed or in developing countries.

5. Conclusion

In conclusion, this study showed that health-related content analysis of school textbooks is done mostly in Spain and the United States and most frequently examines content related to sexuality, STDs, and nutrition. The quality of the content is sometimes inappropriate and requires improvement.

Acknowledgements

This study was supported by a research grant from the Ministry of Health, Labour and Welfare, Japan (2009-chikyukibo-wakate-011, 09151352).

References

1. Bartlett EE. The contribution of school health education to community health promotion: What can we reasonably expect? *Am J Public Health*. 1981; 71:1384-1391.
2. WHO. WHO information series on school health. Healthy Nutrition: An Essential Element of a Health-Promoting School. WHO, 1998. http://who.int/school_youth_health/media/en/428.pdf (accessed May 8, 2009).
3. UNESCO. Textbook quality improvement programme: Support to basic education in Iraq. UNESCO, 2005. <http://unesdoc.unesco.org/images/0013/001394/139428e.pdf> (accessed May 8, 2009).
4. Barrio Cantalejo IM, Ayudarte Larios ML, Hernán García M, Martínez Tapias J, de Haro Castellano JM, Simón Lorda P, Sánchez García M. Presence of current child adolescent health priorities in school textbooks. *Gac Sanit*. 2008; 22:227-231. (in Spanish)
5. Mohammad RF, Kumari R. Effective use of textbooks: A neglected aspect of education in Pakistan. *J Educ Int Dev*. 2007; 3:1.
6. UNESCO. A Comprehensive Strategy for Textbooks and Learning Materials. UNESCO, 2005. <http://unesdoc.unesco.org/images/0014/001437/143736fb.pdf> (accessed May 8, 2009).
7. de Irala J, Urdiain IG and López Del Burgo C. Analysis of content about sexuality and human reproduction in school textbooks in Spain. *Public Health*. 2008; 122:1093-1103.
8. Perrin AJ. Book review: The content analysis guidebook. *Soc Sci Comput Rev*. 2002; 20:365-366.
9. Gavidia Catalán V. Health education in the Spanish school manuals. *Rev Esp Salud Pública*. 2003; 77:275-285. (in Spanish)
10. Granados-Cosme JA, Nasaiya K, Brambila AT. Social actors in HIV/AIDS prevention: Opposition and interests in educational policy in Mexico, 1994-2000. *Cad Saude Publica*. 2007; 23:535-544. (in Spanish)
11. Succi Cde M, Wickbold D, Succi RC. Evaluation of school-books content on the subject of vaccines. *Rev Assoc Med Bras*. 2005; 51:75-79. (in Portuguese)
12. Eichholzer-Helbling M, Ackermann-Liebrich U, Ritzel G. Nutritional references in primary-school textbooks used in Basle and Berne. *Soz Praventivmed*. 1984; 29:82-87. (in German)
13. Kroger F, Yarber WL. STD content in school health textbooks: An evaluation using the worth assessment procedure. *J Sch Health*. 1984; 54:41-44.
14. Beyer CE, Ogletree RJ, Ritzel DO, Drolet JC, Gilbert SL, Brown D. Gender representation in illustrations, text, and topic areas in sexuality education curricula. *J Sch Health*. 1996; 66:361-364.
15. Reiss MJ. The representation of human sexuality in some science textbooks for 14-16 year olds. *Res Sci Technol Educ*. 1998; 16:137-149.
16. D'Onofrio CN, Singer R. Unplanned nutrition education

- in the schools: Sugar in elementary reading texts. *J Sch Health*. 1983; 53:521-526.
17. Baron V. Nutrition messages in language arts and mathematics textbooks used in English elementary schools in Montreal. *J Sch Health*. 1990; 60:452-454.
 18. Tolan PH, Lounsbury JW. Community mental health ideology presented in high school health textbooks: A content analysis. *Community Ment Health J*. 1982; 18:286-296.
 19. Frager AM, Kahn A. How useful are elementary school health textbooks for teaching about hearing health and protection? *Lang Speech Hear Serv Sch*. 1988; 19:175-181.
 20. Baysac MA, Horowitz AM, Ma DS. Oral cancer information in health education textbooks. *J Cancer Educ*. 2004; 19:12-16.
 21. Allen JP, Philliber S, Hoggson N. School-based prevention of teen-age pregnancy and school dropout: Process evaluation of the national replication of the Teen Outreach Program. *Am J Community Psychol*. 1990; 18:505-524.
 22. Grant MJ, Hallman KK. Pregnancy-related school dropout and prior school performance in KwaZulu-Natal, South Africa. *Stud Fam Plann*. 2008; 39:369-382.
 23. Monasch R, Mahy M. Young people: The centre of the HIV epidemic. *World Health Organ Tech Rep Ser*. 2006; 938:15-41; discussion 317-41.
 24. WHO. WHO technical report series 938. Preventing HIV/AIDS in young people. WHO, 2006. http://www.unicef.org/files/PREVENTING_HIV_AIDS_IN_YOUTH_PEOPLE_A_SYSTEMATIC_REVIEW_OF_THE_EVIDENCE_FROM_DEVELOPING_COUNTRIES_WHO_2006.pdf (accessed May 8, 2009).
 25. Pokharel S, Kulczycki A, Shakya S. School-based sex education in Western Nepal: Uncomfortable for both teachers and students. *Reprod Health Matters*. 2006; 14:156-161.
 26. Persson E, Sandström B, Jarlbro G. Sources of information, experiences and opinions on sexuality, contraception and STD protection among young Swedish students. *Adv Contracept*. 1992; 8:41-49.
 27. Yoo H, Lee SH, Kwon BE, Chung S, Kim S. HIV/AIDS knowledge, attitudes, related behaviors, and sources of information among Korean adolescents. *J Sch Health*. 2005; 75:393-399.
 28. Edson F, Kayombo EJ. Knowledge on malaria transmission and its prevention among schoolchildren in Kyela District, south-western Tanzania. *Tanzan Health Res Bull*. 2007; 9:207-210.
 29. Teitelman AM, Bohinski JM, Boente A. The social context of sexual health and sexual risk for urban adolescent girls in the United States. *Issues Ment Health Nurs*. 2009; 30:460-469.
 30. Griffin KW, Botvin GJ, Nichols TR. Long-term follow-up effects of a school-based drug abuse prevention program on adolescent risky driving. *Prev Sci*. 2004; 5:207-212.
 31. Patil V, Solanki M, Kowli SS, Naik VA, Bhalerao VR, Subramanian P. Long-term follow-up of school health education programmes. *World Health Forum*. 1996; 17:81-82.
 32. Stephen JB, James JN, Selene SH, Walter DS. *Teaching health science*. Massachusetts, Jones and Bartlett Publishers, Sudbury, MA, USA, 1997.
 33. Tones K, Tilford S. *Health promotion: Effectiveness, efficiency and equity*. Nelson Thornes Publishers Ltd, Gloucester, UK, 2001.
 34. Faggiano F, Galanti MR, Bohrn K, Burkhart G, Vigna-Taglianti F, Cuomo L, Fabiani L, Panella M, Perez T, Siliquini R, van der Kreeft P, Vassara M, Wiborg G; EU-Dap Study Group. The effectiveness of a school-based substance abuse prevention program: EU-Dap cluster randomised controlled trial. *Prev Med*. 2008; 47:537-543.
 35. Resnicow K, Reddy SP, James S, Gabebedeen Omardien R, Kambaran NS, Langner HG, Vaughan RD, Cross D, Hamilton G, Nichols T. Comparison of two school-based smoking prevention programs among South African high school students: Results of a randomized trial. *Ann Behav Med*. 2008; 36:231-243.
 36. Azeredo R, Stephens-Stidham S. Design and implementation of injury prevention curricula for elementary schools: Lessons learned. *Inj Prev*. 2003; 9:274-278.
 37. UNICEF. *The state of the world's children 2003*. UNICEF, 2003. <http://www.unicef.org/sowc03/contents/pdf/SOWC03-eng.pdf> (accessed May 8, 2009).
 38. UNESCO. *Overcoming inequality: Why governance matters*. UNESCO, 2008. <http://unesdoc.unesco.org/images/0017/001776/177683E.pdf> (accessed May 8, 2009).

(Received October 26, 2010; Revised February 5, 2011; Accepted March 10, 2011)

Medical students' choice of specialty and factors determining their choice: A cross-sectional questionnaire survey in Melaka-Manipal Medical College, Malaysia

Yu Wei Chew¹, Sudeash Rajakrishnan¹, Chin Aun Low¹, Prakash Kumar Jayapalan¹, Chandrashekhar T. Sreeramareddy^{2,*}

¹Melaka-Manipal Medical College (Melaka campus), Jalan Batu Hampar Bukit Baru, Melaka, Malaysia;

²Department of Community Medicine, Melaka-Manipal Medical College (Melaka campus), Jalan Batu Hampar Bukit Baru, Melaka, Malaysia.

Summary

Information about medical students' choice of specialty can be helpful for planning health manpower. However, such information from medical students in Malaysian medical schools is lacking. We carried out a cross-sectional questionnaire survey among fourth- and fifth-year medical undergraduate students at Melaka-Manipal Medical College. A total of 425 students responded to the survey questionnaire. Nearly a quarter of the students indicated internal medicine as their choice of specialty. Other choices were general surgery (13.2%), pediatrics (11.3%), orthopedics (12.7%) and obstetrics & gynecology (Ob/Gyn) (12.1%). Female students (OR 1.91; 95% CI 1.18-3.08), fourth-year students (OR 1.9; 95% CI 1.15-3.12), and students who reported a higher self-rated knowledge of their subject of choice were more likely to choose internal medicine and allied specialties (OR 1.53; 95% CI 1.07-2.19). The influence of teaching faculty and consultants at the teaching hospitals (74.4%) and inspiration obtained during clinical postings (71.9%) were the factors which were rated by the most students as 'important' for choosing a specialty. About half of the students intended to pursue their postgraduate studies in Malaysia, most of the rest in the United Kingdom or Australia. While internal medicine and surgical subspecialties were preferred, students were not inclined towards primary care or diagnostic subspecialties. Incentives should be provided and other measures should be taken to make these branches more attractive.

Keywords: Undergraduate medical education, postgraduate training, specialty, Malaysia

1. Introduction

Medical education requires undergraduate students to study a wide range of medical subjects. Medical careers begin undifferentiated; during their postgraduate training, doctors specialize in a particular field of practice. Medical students can be seen as a relatively

undifferentiated, multi-potent 'stem doctors' (1) capable of entering any field of practice; specialization turns them ultimately into fully-differentiated specialists whose practice is almost entirely confined to one specialized branch of medicine. Information about students' preferred choice of specialist training may be useful in planning national health manpower programs and in identifying the specialties with low preference in order to undertake measures to make these specialties more attractive. Such information may also help medical educators to plan training facilities and define selection criteria.

Medical students' decisions about specialist training may be influenced by several factors. However, very little is known about the factors that influence medical students in South and Southeast Asia. Based on the

*Address correspondence to:

Dr. Chandrashekhar T. Sreeramareddy, Department of Community Medicine Melaka Manipal Medical College, Jalan Batu Hampar, Bukit Baru, Melaka 75150, Malaysia.

e-mail: chandrashekharats@yahoo.com

existing literature, these factors are thought to include higher income, prestige, hospital-based practice (2), experience during clinical postings, inspiration given by academic teaching faculty, working hours, and flexibility of working arrangements (3,4). Personal intelligence and career opportunities also play a role (4). Besides the afore-mentioned factors, advice from family, friends, or practicing specialists may also influence students in deciding their future specialty. In addition, personal life experiences, interest in community-based settings, and passion for providing continuous care to patients may also pave the way to a specialty choice.

Several studies from different countries have reported preferred choices of medical specialist training and factors affecting medical students' choice of specialty. A study from the United States of America (USA) reported that no single factor dominates a student's choice for primary care, and higher income, more prestige, and hospital-based practice play an important role in the choice of non-primary care specialties (2). Work culture, working conditions, and personal experience with discipline-based medicine in the early postgraduate years were reported to be important factors among Australian undergraduate medical students (3). In New Zealand (5), medicine, surgery, general practice (GP), pediatrics, and obstetrics & gynecology (Ob/Gyn). were the most popular choices and faculty and clinical posting experiences were reported as the main influencing factors. A study from Canada (6) compared family medicine with other specialties and found that older students, those concerned with medical lifestyles, those who were living in smaller communities during high school, and those more interested in varied-scope practice and less interested in hospital-oriented practice preferred family medicine to other specialties. Personal intelligence, ability preferences, and career opportunities were important factors among Chinese medical undergraduate students (7). A similar study from Jordan (8) reported that surgery, Ob/Gyn, internal medicine, and pediatrics were preferred specialties, and the specialty's reputation, anticipated income, focus on urgent care, intellectual content of the specialty, and individual's competency were the factors most influencing their choice. Preclinical and clinical experiences as well as role models were the factors reported from Japan (4). Prestige, money, and personal development were reported as important factors among Turkish undergraduate medical students (9). However, there are no such data about choice of specialty and factors influencing choice among Malaysian medical students. The objectives of our survey were to identify medical students' choice of specialty and the factors considered most important by medical students in Malaysia when choosing their specialty.

2. Methods

2.1. Study design and setting

The study was designed as a cross-sectional self-administered questionnaire-based survey. In Malaysia, undergraduate medical education is offered by both publicly-funded and private medical schools. The undergraduate medical program is of five years' duration with compulsory rotational housemanship after completion of the final qualifying examination. The curricula in most medical schools incorporate problem-based learning (PBL), with more emphasis on tutorials than lectures. In most medical schools, clinical rotations start from the third year. Students undergo clinical training in major medical, surgical, and allied subjects during each academic year, including senior clerkships during the fifth year. Postgraduate specialist training facilities are mostly available in publicly-funded university medical schools; recently, a few private medical schools have also initiated postgraduate specialist training.

This survey was carried out among the undergraduate medical students of Melaka-Manipal Medical College (MMMC), Melaka Campus, Malaysia. MMMC is a private medical college which offers a twinning medical course and is affiliated with Manipal University, India. Students of MMMC undergo 2.5 years of basic sciences and introductory clinical training on the Manipal Campus in India. Subsequently, another 2.5 years of clinical training takes place at the Melaka Campus in Malaysia. The medical degree Bachelor of Medicine and Bachelor of Surgery (MBBS) conferred by Manipal University is recognized by the Government of Malaysia and the Malaysian Medical Council (MMC) and is accredited by the Malaysian Qualifications Agency (MQA). MMMC is also listed in the WHO directory of recognized medical colleges and in the International Medical Education Directory (IMED) of the Educational Commission for Foreign Medical Graduates (ECFMG).

2.2. Participant

All fourth- and fifth-year undergraduate medical students studying at Melaka-Manipal Medical College, Melaka campus, were eligible to participate in the survey. These students were chosen because they had already completed at least one clinical rotation in all clinical subjects.

2.3. Questionnaire

After a detailed review of existing literature and informal discussions with medical students and teaching faculty at MMMC, a structured questionnaire was developed in English. A draft questionnaire

was subjected to a validation process in which the questionnaire was given to a group of 15 medical students to obtain their feedback and check for item appropriateness and comprehensiveness. The questionnaire was revised based on the responses and feedback received. The questionnaire began with instructions to the participants followed by demographic data. The questions regarding the choice of subject in which the students intended to specialize were open-ended. The participants were instructed to identify their three most preferred subjects, *i.e.*, their first, second, and third choices. A list based on the review of literature of 16 reasons for and factors associated with the students' choice of specialty was also included. The participants were asked to rate the importance of these reasons and factors as 'least important' to 'most important' on a five-point Likert scale. The questionnaire also contained a few questions regarding their self-rated knowledge on their preferred subject choice on a five-point Likert scale and regarding the country where they intended to pursue their postgraduate training.

2.4. Data collection

Permission/approval to carry out the survey was obtained from college authorities and the Research Committee. During August and September 2010, data collection was done by members of our team, namely Chew Yu Wei (CYW), Sudeash Rajakrishnan (SR), Low Chin Aun (LCA), and Prakash Kumar Jayapalan (PKJ). Structured questionnaires were distributed to the students before or after small group teaching sessions. All the students in their fourth or fifth years were invited to participate in the survey after being briefed about the objectives. The students were also informed that participation in the survey was voluntary and not compulsory. Assurances of anonymity and confidentiality of the information were given. Consent was sought from all the students before the questionnaires were administered. The students were not required to enter any identifiable personal details like name, address, or roll number on the questionnaire. Completed questionnaires were collected by the research team.

2.5. Variables

The 16 possible reasons and factors for the student's choice of specialty were grouped into 'personal' and 'professional' reasons/factors. We computed separate scores for personal reasons and for professional reasons by adding the Likert scores. We used first choice of specialty in our multivariate analysis to identify factors determining the choice of internal medicine and allied subjects (*i.e.*, internal medicine, pediatrics, cardiology, neurology, emergency medicine, primary care medicine,

etc.). The other category was surgical branches or specialties, including general surgery, orthopedics, obstetrics, gynecology, otolaryngology, *etc.* The choice of internal medicine and allied subjects was used as a dependant variable. We used demographic variables, year of study, self-rated knowledge about their first choice, and reasons/factors influencing the choice (Likert scores for personal reasons and for professional reasons) as independent variables for univariate and multivariate analyses.

2.6. Statistical analysis

Statistical analyses were carried out using Statistical Package for Social Sciences (SPSS) version 14. We generated summary statistics for demographic variables and choice of medical specialty. We carried out univariate and multivariate analyses to assess the factors determining the choice of internal medicine and allied subjects. We calculated crude and adjusted odds ratios (OR) and their 95% confidence intervals (95% CI). A *p* value less than 0.05 was considered significant.

3. Results

3.1. Response rates and demographic characteristics

Out of 524 students in their fourth- or fifth-year MBBS program, 425 students responded to the questionnaire, giving an overall response rate of 81.2%. Of these students, 23 had not completed all the sections of the questionnaires and were not included in the analysis. Thus 402 completed questionnaires were analyzed. Of these students, 243 were in their fourth year and 159 were in their fifth year. The students' median age was 23 years (mean = 23.6 years, S.D. = 1.02). Demographic characteristics of the respondents according to gender are shown in Table 1. About 73% of the students were single, 26% were currently in a relationship. The ethnic distribution of students was nearly a third each for Malay, Chinese and Indian. The vast majority (97%) of the students were Malaysians; 12 students were from Seychelles or Sri Lanka. About 9% of the students had a medical doctor parent; 40% had one or more siblings who were doctors.

3.2. Choice of medical specialty

Thirty-one students (7.7%) did not indicate any intention to specialize in any subject. For nearly one-fourth of the students, internal medicine was their first, second, as well as third choice. General surgery (13.2%), pediatrics (11.3%), orthopedics (12.7%) and Ob/Gyn (12.1%) were indicated as first choice by almost equal percentages of students (Table 2). Men were more likely to choose surgical branches while women were more likely to choose internal medicine

Table 1. Socio-demographic characteristics of participants

	Male (n = 177)	Female (n = 225)	Total (n = 402)	P
Nationality				
Malaysian	173 (97.7%)	217 (96.4%)	390 (97.0%)	0.448
Non-Malaysian	4 (2.3%)	8 (3.6%)	12 (3.0%)	
State of residence				
West Malaysia				0.421
North	47 (27.2%)	71 (32.7%)	118 (30.2%)	
South	115 (66.5%)	136 (62.7%)	251 (64.4%)	
East Malaysia	11 (6.4%)	10 (4.6%)	21 (5.4%)	
Ethnicity				
Malay	46 (26.0%)	79 (35.1%)	125 (31.1%)	0.078
Indian	56 (31.6%)	75 (33.3%)	131 (32.6%)	
Chinese	69 (39.0%)	62 (27.6%)	131 (32.6%)	
Others	6 (3.4%)	9 (4.0%)	15 (3.7%)	
Religion				
Islam	49 (27.7%)	87 (38.7%)	136 (33.8%)	0.135
Buddhist	47 (26.6%)	50 (22.2%)	97 (24.1%)	
Christian	25 (14.1%)	23 (10.2%)	48 (11.9%)	
Hindu	43 (24.3%)	55 (24.4%)	98 (24.4%)	
Others	13 (7.3%)	10 (4.5%)	23 (5.8%)	
Year of study				
Fourth	95 (53.7%)	148 (65.8%)	243 (60.4%)	0.014
Fifth	82 (46.3%)	77 (34.2%)	159 (80.5%)	
Parents' occupation				
Doctor	15 (8.5%)	22 (9.8%)	37 (9.2%)	0.650
Others	162 (91.5%)	203 (90.2%)	365 (90.8%)	
Siblings' occupation				
Doctor	66 (37.3%)	95 (42.2%)	161 (40.0%)	0.316
Others	111 (62.7%)	130 (57.8%)	241 (60.0%)	

Table 2. Specialty preferences among fourth- and fifth-year medical students

Subject of choice for specialization	First choice (n = 371)	Second choice (n = 333)	Third choice (n = 259)	Total (n = 963)
Medicine	97 (26.1%)	75 (22.5%)	57 (22.0%)	229 (23.8%)
Surgery	49 (13.2%)	61 (18.3%)	29 (11.3%)	139 (14.4%)
Pediatrics	42 (11.3%)	22 (6.6%)	20 (7.7%)	84 (8.7%)
Ob/Gyn	45 (12.1%)	39 (11.7%)	32 (12.4%)	116 (12.0%)
Orthopedics	47 (12.7%)	28 (8.4%)	26 (10.0%)	101 (10.5%)
Otolaryngology	16 (4.4%)	33 (9.9%)	14 (5.4%)	63 (6.5%)
Ophthalmology	7 (1.9%)	14 (4.2%)	15 (5.8%)	36 (3.8%)
Psychiatry	12 (3.2%)	7 (2.1%)	15 (5.8%)	34 (3.5%)
Public Health	12 (3.2%)	11 (3.3%)	8 (3.1%)	31 (3.2%)
Emergency Medicine	11 (3.0%)	13 (3.9%)	11 (4.2%)	35 (3.7%)
Anesthesia	14 (3.8%)	12 (3.7%)	10 (3.9%)	36 (3.8%)
Radiology	9 (2.4%)	11 (3.3%)	11 (4.2%)	31 (3.2%)
Others	10 (2.7%)	7 (2.1%)	11 (4.2%)	28 (2.9%)

subjects. Ob/Gyn was indicated by 37 (16.4%) female students and by only eight (4.5%) male students. Nearly 50% of the students wanted to undergo specialty training in Malaysia, about 45% in the United Kingdom, followed in popularity by Australia.

3.3. Factors affecting choice of medicine and allied subjects for specialist training

By univariate analysis (Table 3), the proportion of female students choosing medical subjects was significantly higher than that of males (39% versus 26%, OR 1.83, 95% CI 1.19-2.81). Fourth-year students were 1.56 times more likely to choose an internal

medicine specialty than fifth-year students (39.4% versus 29.3%, OR 1.56, 95% CI 1.03-2.38). Students with a higher self-reported knowledge about their subject of choice were 1.81 times more likely to select that subject (OR 1.81, 95% CI 1.25-2.64). Students who rated personal factors as 'important' or 'very important' were 1.06 times more likely to choose a medical subject ($p = 0.01$, 95% CI 1.02-1.12). Similarly the professional factors score also differed significantly (OR 1.06, 95% CI 1.01-1.10). The following factors were not statistically significant: age ($p = 0.917$), marital status ($p = 0.75$), postgraduate country ($p = 0.192$), sibling doctors ($p = 0.238$).

The results of multivariate analysis are shown in

Table 3. Univariate analysis of medical subjects as student's choice of specialisation

Factor/variable	Medical specialty	Odds Ratio (95% CI)	<i>p</i>
Age (mean and S.D.)*	23.6 years	1.01 (0.82-1.24)	0.917
Gender			
Male	46/177 (26)	1	
Female	88/225 (39)	1.83 (1.19-2.81)	0.006
Ethnicity			
Indian	51/131 (38.9)	1	
Chinese	46/146 (31.5)	1.52 (0.90-2.55)	0.120
Malay	37/125 (29.6)	1.38 (0.85-2.27)	0.197
Marital status			
In a relationship	35/109 (32.1)	1	
Single	99/293 (33.8)	0.93 (0.58-1.48)	0.750
Year of study			
Year 5	63/160 (39.4)	1	
Year 4	71/242 (29.3)	1.56 (1.03-2.38)	0.037
Country for postgraduate studies			
Malaysia	61/187 (32.6)	1	
Non-Malaysia	72/184 (39.1)	1.33 (0.87-2.03)	0.192
Doctor sibling			
No sibling doctor	48/166 (30.0)	1	
At least one doctor	86/241 (35.7)	1.30 (0.84-1.99)	0.238
Knowledge score (mean and S.D.)*	2.2 (0.6)	1.81 (1.25-2.64)	0.002
Personal score (mean and S.D.)*	27.6 (4.6)	1.06 (1.02-1.12)	0.010
Professional score (mean and S.D.)*	26.0 (5.2)	1.06 (1.01-1.10)	0.090

* For these variables we compared medical subjects with 'other' subjects.

Table 4. Female students were 1.91 times more likely to choose internal medicine than males (OR 1.91, 95% CI 1.18-3.08). Fourth-year students were 1.9 times more likely to select internal medicine than fifth-year students (OR 1.9, 95% CI 1.15-3.12). The score of self-rated knowledge on subject of choice was associated with choice of subject (OR 1.53, 95% CI 1.07-2.19). Professional factors also determined the choice of an internal medicine speciality (OR 1.06, 95% CI 1.00-1.12). Other factors like age ($p = 0.339$), country of choice for postgraduate education ($p = 0.296$), and personal factors ($p = 0.647$) were not statistically significant.

Participants were asked to rate the importance of 16 factors that may have influenced their choice of specialty; the ratings are shown in Table 5. Among personal factors, 74.4% of the students reported the 'influence of teaching faculty and consultants at teaching hospitals' and 53.8% 'possession of competencies required for the specialty' as 'important'. Among professional factors, 71.9% students responded 'inspiration obtained during clinical postings' and 63.4% 'suitability of the specialty to their own personality' as important.

4. Discussion

Our survey results showed that internal medicine was the most preferred subject for specialty training, followed by general surgery, pediatrics, orthopedics and Ob/Gyn. Most students preferred Malaysia, the United Kingdom, or Australia for their postgraduate

Table 4. Multivariate analysis of students' choice of specialty

Factor/variable	Odds Ratio (95% CI)	<i>p</i>
Age	1.12 (0.88-1.43)	0.339
Gender		
Male	1	
Female	1.91 (1.18-3.08)	0.008
Ethnicity		
Malay	1	
Chinese	1.77 (0.98-3.20)	0.060
Indian	1.76 (1.01-3.07)	0.045
Year of Study		
Year 4	1	
Year 5	1.89 (1.15-3.12)	0.012
Country for postgraduate training		
Malaysia	1	
Non-Malaysia	1.28 (0.81-2.04)	0.296
Knowledge	1.53 (1.07-2.19)	0.019
Personal score	1.02 (0.95-1.08)	0.647
Professional score	1.06 (1.00-1.12)	0.045

education. Univariate analysis showed students in their fourth year and female students to be more likely to choose internal medicine and allied subjects for their specialist training. Personal factors and students' (good) self-rated knowledge of the specialty also influenced their choice of internal medicine and allied subjects for specialist training. Multivariate analysis showed female gender, year of study (fourth year), a higher self-rated knowledge, and professional factors to be determinants of the choice of internal medicine and allied subjects for specialist training.

To the best of our knowledge, studies about medical students' choice of specialty have not been carried out in

Table 5. Reasons or factors considered by medical students when choosing a specialty

Reasons/factors	Important number (%)	Very important number (%)
Personal factors		
1. Influence of teaching faculty and hospital consultants	134 (40.2)	125 (34.2)
2. Advice from parents/siblings/relatives	76 (20.8)	34 (9.3)
3. Advice from friends/seniors	89 (24.3)	23 (6.3)
4. Possession of competency needed for this specialty	127 (34.7)	70 (19.1)
5. Financial rewards	82 (22.4)	46 (12.6)
6. Less work pressure and better quality of life	99 (27.0)	57 (15.6)
7. Less working hours/ability to spend time with family	98 (26.8)	71 (19.4)
8. Personal experience pertaining to the field	129 (35.2)	56 (15.3)
Professional factors		
9. Inspiration during clinical posting	140 (38.3)	123 (33.6)
10. Advice from practicing doctors	128 (35.0)	53 (14.5)
11. Lack of experts in the field in Malaysia	91 (24.9)	37 (10.1)
12. Continuous care for patients	138 (37.7)	47 (12.8)
13. No night calls	56 (15.3)	60 (16.4)
14. Preference for community-based settings	80 (21.9)	30 (8.2)
15. Suitability of specialty to own personality	149 (40.7)	83 (22.7)
16. Very challenging nature of this field	145 (39.6)	75 (20.5)

There are missing values, because in each case, a few students did not respond.

Malaysia or South and Southeast Asia. Our results can help medical educationists and policy makers to plan postgraduate training and health manpower programs in Malaysia. Such information may also provide a basis for the development of strategies to enhance the attractiveness of specialties which have inadequate trained manpower. Similar to previous surveys, only a small proportion of the students indicated diagnostic branches, primary care, or public health as their choice for specialist training (9,15).

A number of studies from different countries have shown that choices of specialist training by undergraduate students vary (1-16). Results of these studies have shown that students are usually inclined towards medical or surgical specialties or subspecialties. The most preferred specialty of students in our study was internal medicine. Internal medicine and allied subjects were preferred by the plurality of students in our study, similar to results reported by studies in other countries (9,10-14). However, contrary to the findings of our study, students in Jordan and Greece preferred surgical branches over medical branches (8,15). Surprisingly, in a survey from Turkey, one-fourth of the students preferred subspecialty cardiology for specialization (9). We note that some students in our college did not indicate any specialty preference, while only a small proportion wanted to specialize in public health or primary care. This trend is similar to results reported from developed countries (5,6,10,13,15). Further, no one indicated a preference for a preclinical subject such as biochemistry, microbiology, or pathology; these subjects are thought to be less lucrative and are not well recognized as specialties in the medical fraternity (8,9).

There could be several reasons for internal medicine being medical students' most preferred specialty. Internal medicine specialists are known as 'doctor's

doctors' who are always called upon for consultations by other physicians (17). Besides, we expect that television series like 'House' and 'ER' may also have played a role in influencing these students to choose internal medicine. Internal medicine may also have been considered as an interesting prospect because it opens up more choices for subspecialization. The students may also be aware of the growing burden of chronic non-communicable diseases in Malaysia, which increases the demand for internists (18). Most people want to become doctors to care for patients, and this desire matches the continuous care required by patients treated in internal medicine.

In our study, gender differences were noted in the preference for certain specialties. Female students were more likely to prefer internal medicine and allied subjects over surgical specialties. Female students were more likely to choose Ob/Gyn than their male counterparts. This result is similar to findings from Japan, Jordan, Turkey, and Switzerland (4,8,9,16). Female students were more likely to choose internal medicine and allied subjects because they involve less physical work than surgical fields like general surgery and orthopedics. In Malaysia as well as the countries mentioned above, conservative Islamic societies, women generally prefer to consult a female doctor for pregnancy or gynecological problems. More women might be inclined toward Ob/Gyn for this reason. Our study showed that fourth-year and final-year students preferred medical over surgical specialties; this is in agreement with the studies reported from Jordan and the USA (8,10,13), where students' progress through medical school is reported to change their choice from surgical specialties to internal medicine and allied specialties.

Some studies have also explored factors that influence the choice of specialist training

(3,4,7-9,14). These studies have reported that financial considerations, prestige, personal competencies as well as intelligence, and clinical experience were the main factors influencing decisions to choose a specialty. We elucidated all these factors using a Likert scale. Our study found both personal and professional factors to be significant. This is in agreement with the results of studies from Japan, Canada, Jordan, Turkey, and the USA (4,6,8-10,13,14). Our survey found that, among the personal factors, the influence of teaching faculty and hospital consultants was the most important, while among professional factors, inspiration during clinical postings, the challenging nature of a specialty, and suitability to the student's personality were 'important'. The approach we used to determine the factors influencing the choice of subject was different from other studies from Australia (3), Canada (6), and Taiwan (7), which have analyzed the factors with different statistical methods, while a study from Japan used a qualitative approach (4). Studies from Jordan (8) and Turkey (9) only listed the factors and did not use any analytical methods. This issue of reasons or factors influencing choice of specialty is complex and often more than one factor may be involved in decision making. Future studies should focus more on a qualitative than a quantitative approach.

Most students intended to undergo specialist training in Malaysia, though some students indicated the United Kingdom and Australia as alternatives. More credibility, their better reputation, and the worldwide recognition of postgraduate courses in these countries may be the reasons for choosing these countries (17). We are unsure if migration was a motive for seeking entry into these countries for postgraduate training. Malaysia remained the first choice because the cost of training is nominal and the course structure is tailored to suit the Malaysian health care system and the disease burden. On the other hand, postgraduate training courses in Malaysia are available in only three public universities.

However, our survey was conducted only among clinical-phase students from one private medical school. Therefore, our findings may not reflect the true picture of medical students' choice of specialty in all medical schools in Malaysia. Though our response rate was fairly high, more female than male students responded, we cannot rule out some selection bias.

5. Conclusion

Though internal medicine and allied specialties and surgical specialties were indicated as preferred subjects for specialization, the students surveyed were not inclined towards primary care or diagnostic specialties. Incentives and other measures must be put in place to make these branches more attractive to young doctors. Qualitative studies are necessary to assess the complex

issue of factors influencing choices of specialty. Further studies should be carried out on a representative sample of students at other medical schools of Malaysia.

Acknowledgements

The authors are thankful to the Chief Executive Officer, Dean, and Research Committee of Melaka Manipal Medical College for giving us this opportunity to carry out this student research project. We also thank the Department of Community Medicine for their support and encouragement throughout this project. Last but not least, we thank our fellow students who participated in this survey.

References

1. Petrides KV, McManus IC. Mapping medical careers: Questionnaire assessment of career preferences in medical school applicants and final-year students. *BMC Med Educ.* 2004; 4:18.
2. Gorenflo DW, Ruffin MT 4th, Sheets KJ. A multivariate model for specialty preference by medical students. *J Fam Pract.* 1994; 39:570-576.
3. Harris MG, Gavel PH, Young JR. Factors influencing the choice of specialty of Australian medical graduates. *Med J Aust.* 2005; 183:295-300.
4. Saigal P, Takemura Y, Nishiue T, Fetters MD. Factors considered by medical students when formulating their specialty preferences in Japan: Findings from a qualitative study. *BMC Med Educ.* 2007; 7:31.
5. Zarkovic A, Child S, Naden G. Career choices of New Zealand junior doctors. *N Z Med J.* 2006; 119:U1851.
6. Wright B, Scott I, Woloschuk W, Brenneis F, Bradley J. Career choice of new medical students at three Canadian universities: Family medicine *versus* specialty medicine. *CMAJ.* 2004; 170:1920-1924.
7. Chang PY, Hung CY, Wang KI, Huang YH, Chang KJ. Factors influencing medical students' choice of specialty. *J Formos Med Assoc.* 2006; 105:489-496.
8. Dikici MF, Yaris F, Topsever P, Tuncay Muge F, Gurel FS, Cubukcu M, Gorpelioglu S. Factors affecting medical students in formulating their specialty preferences in Jordan. *BMC Med Educ.* 2008; 8:32.
9. Dikici MF, Yaris F, Topsever P, Tuncay Muge F, Gurel FS, Cubukcu M, Gorpelioglu S. Factors affecting choice of specialty among first-year medical students of four universities in different regions of Turkey. *Croat Med J.* 2008; 49:415-420.
10. Dorsey ER, Jarjoura D, Rutecki GW. Influence of controllable lifestyle on recent trends in specialty choice by US medical students. *JAMA.* 2003; 290:1173-1178.
11. Paik JC, Howard G, Lorenz RG. Postgraduate choices of graduates from medical scientist training programs, 2004-2008. *JAMA.* 302:1271-1273.
12. Fukuda Y, Harada T. Gender differences in specialty preference and mismatch with real needs in Japanese medical students. *BMC Med Educ.* 2010; 10:15.
13. Newton DA, Grayson MS. Trends in career choice by US medical school graduates. *JAMA.* 2003; 290:1179-1182.
14. Hauer KE, Durning SJ, Kernan WN, Fagan MJ, Mintz M, O'Sullivan PS, Battistone M, DeFer T, Elnicki

- M, Harrell H, Reddy S, Boscardin CK, Schwartz MD. Factors associated with medical students' career choices regarding internal medicine. JAMA. 2008; 300:1154-1164.
15. Mariolis A, Mihas C, Alevizos A, Gizlis V, Mariolis T, Marayiannis K, Tountas Y, Stefanadis C, Philalithis A, Creatsas G. General Practice as a career choice among undergraduate medical students in Greece. BMC Med Educ. 2007; 7:15.
16. Buddeberg-Fischer B, Klaghofer R, Abel T, Buddeberg C. Swiss residents' speciality choices – impact of gender, personality traits, career motivation and life goals. BMC Health Serv Res. 2006; 6:137.
17. Arah OA, Ogbu UC, Okeke CE. Too poor to leave, too rich to stay: Developmental and global health correlates of physician migration to the United States, Canada, Australia, and the United kingdom. Am J Public Health. 2008; 98:148-154.

(Received October 29, 2010; Revised January 16, 2011; Accepted March 10, 2011)

Impaired function of bone marrow-derived endothelial progenitor cells in murine liver fibrosis

Katsuya Shirakura^{1,2}, Haruchika Masuda¹, Sang-Mo Kwon⁴, Syotaro Obi¹, Rie Ito¹, Tomoko Shizuno¹, Yusuke Kurihara¹, Tetsuya Mine², Takayuki Asahara^{1,3,*}

¹Department of Regenerative Medicine Science, Tokai University School of Medicine, Isehara, Japan;

²Internal Medicine (Gastroenterology), Tokai University School of Medicine, Isehara, Japan;

³Vascular Regeneration Research Group, Institute of Biomedical Research and Innovation, Kobe, Japan;

⁴Laboratory of Vascular Medicine and Stem Cell Biology, CHA University, Seoul, Korea.

Summary

Liver fibrosis (LF) caused by chronic liver damage has been considered as an irreversible disease. As alternative therapy for liver transplantation, there are high expectations for regenerative medicine of the liver. Bone marrow (BM)- or peripheral blood-derived stem cells, including endothelial progenitor cells (EPCs), have recently been used to treat liver cirrhosis. We investigated the biology of BM-derived EPC in a mouse model of LF. C57BL/6J mice were subcutaneously injected with carbon tetrachloride (CCl₄) every 3 days for 90 days. Sacrificed 2 days after final injection, whole blood (WB) was collected for isolation of mononuclear cells (MNCs) and biochemical examination. Assessments of EPC in the peripheral blood and BM were performed by flow cytometry and EPC colony-forming assay, respectively, using purified MNCs and BM c-KIT⁺, Sca-1⁺, and Lin⁻ (KSL) cells. Liver tissues underwent histological analysis with hematoxylin/eosin/Azan staining, and spleens were excised and weighed. CCl₄-treated mice exhibited histologically bridging fibrosis, pseudolobular formation, and splenomegaly, indicating successful induction of LF. The frequency of definitive EPC-colony-forming-units (CFU) as well as total EPC-CFU at the equivalent cell number of 500 BM-KSL cells decreased significantly ($p < 0.0001$) in LF mice compared with control mice; no significant changes in primitive EPC-CFU occurred in LF mice. The frequency of WB-MNCs of definitive EPC-CFU decreased significantly ($p < 0.01$) in LF mice compared with control mice. Together, these findings indicated the existence of impaired EPC function and differentiation in BM-derived EPCs in LF mice and might be related to clinical LF.

Keywords: Liver fibrosis, carbon tetrachloride, endothelial progenitor cells, differentiation

1. Introduction

Since the discovery of endothelial progenitor cells (EPC) in 1997 (1), many researchers have demonstrated the critical role of bone marrow (BM)-derived EPC in postnatal vasculogenesis through pivotal bioactivities, mobilization, homing, migration, differentiation, and proliferation in angiogenic tissues (2).

Based on this 'dogma', the number of circulating EPC is considered to reflect *in vivo* vasculogenic activity under pathophysiological conditions. For example, in a physiological feature, the menstrual cycle of human females is reportedly to lead to cyclic fluctuations in the number of circulating EPC (3).

On the other hand, pathological features, such as cardiovascular risk factors, including coronary heart disease or heart failure (4), diabetes mellitus (5), hypercholesterolemia (6), and smoking (7) have been reported to decrease the number of circulating EPC, indicating an impairment of EPC differentiation and/or mobilization. Recently, chronic inflammatory disorders, such as ulcerative colitis (8), rheumatoid arthritis (9),

*Address correspondence to:

Dr. Takayuki Asahara, Department of Regenerative Medicine Science, Tokai University School of Medicine Science, Isehara, Japan.

e-mail: asa777@is.icc.u-tokai.ac.jp

uremia (10), and Alzheimer's disease (11) also have been reported to decrease the number of BM-derived EPC, indicating the potential value of monitoring circulating EPC levels as a diagnostic biomarker of individual diseases.

However, in hepatological view, there are few scientific or clinical studies on EPC kinetics in chronic inflammatory liver injury. Using a murine liver fibrosis (LF) model induced by injection of carbon tetrachloride (CCl_4), we recently used an EPC colony forming assay of ancestral stem/progenitors, lineage negative, c-KIT⁺, Sca-1⁺, and Lin⁻ (KSL) cells to show that BM-EPC production was impaired in LF.

In the present study, we used our established model to further investigate BM-derived EPC bioactivity, particularly its potential for differentiation in LF.

2. Materials and Methods

2.1. Animals

Male C57BL/6J mice were purchased at 6 weeks of age from Crea Japan, Inc. (Tokyo, Japan). All animal experiments were conducted in accordance with the institutional guidelines of Tokai University School of Medicine (Isehara, Japan).

2.2. Preparation of the liver fibrosis model

To induce LF, mice were subcutaneously injected with CCl_4 (1 mL/kg body weight) mixed with olive oil every 3 days for 90 days. Control mice were injected with olive oil alone (12). All mice were sacrificed 2 days after the last injection. After liver tissues were obtained, hematoxylin and eosin (H-E) and Azan staining were performed. In addition, the animals' bodies were weighted, and their spleens also were separately weighed.

2.3. Isolation of whole blood mononuclear cells (WB-MNCs) and biochemical examinations

Blood samples were collected by intracardiac needle aspiration into heparinized containers. MNCs and plasma were isolated by density-gradient centrifugation (Histopaque 1083; Sigma-Aldrich, Missouri, USA), and erythrocytes were lysed with ammonium chloride. Nucleated cells were washed twice with phosphate-buffered saline/ethylenediaminetetraacetic acid (PBS-EDTA) to eliminate platelets. Biochemical examinations of blood were performed by the Central Clinical Laboratory of Tokai University Hospital (Isehara, Japan) and SRL (Atsugi, Japan). Blood was analyzed for aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ -GTP), alkaline phosphatase (ALP), total bilirubin, total protein, albumin, and hyaluronic acid (HA).

2.4. Isolation of BM-KSL cells

A BM stem cell population of KSL cells was isolated by cell sorter, FACS Aria (Becton Dickinson; BD, New Jersey, USA), according to the reported protocol (13), as described below. Whole BM cells were harvested from mouse tibias and femurs as described previously (14), then washed with PBS-EDTA, followed by ammonium chloride hemolysis to remove erythrocytes.

Isolated BM-MNCs were initially stained for 20 min at 4°C with a lineage-positive antibody cocktail containing CD45R/B220 (BD), TER119 (BD), CD3e (BD), CD11b (BD), Ly-6G, and Ly6C (Gr-1) (BD). After labeling the lineage positive (Lin⁺) antibodies with biotin-labeled magnetic beads, cells were subjected to a negative selection process with a magnetic cell sorting system (MACS). Lin-negative (Lin⁻) cells were counted and then incubated for 20 min at 4°C with rat-fluorescein isothiocyanate anti-mouse Ly-6A/E (Sca-1) (BD) and rat-PE CD117 (c-KIT) (BD), washed three times, and resuspended in 20% Iscove's modified Dulbecco medium (GIBCO, Invitrogen, California, USA). Fluorescein isothiocyanate-conjugated Sca-1 and phycoerythrin-conjugated c-KIT double-positive cells were then obtained by FACS.

The absolute number of BM stem cells was calculated by multiplying the proportion of KSL cells by the total number of Lin⁻ cells.

2.5. EPC colony forming assay

The vasculogenic potential of BM-KSL cells as a stem cell fraction of BM-derived EPCs (15) was assessed using an EPC colony-forming assay. A total of 500 BM stem cells per dish were seeded into a 35-mm hydrophilic tissue culture dishes (Falcon, BD), and EPC colony-forming-units (CFUs) were counted 7 days later. To characterize the EPC colony-derived cells, adherent colonies were stained with Alex 488-conjugated Griffonia simplicifolia isolectin B4 (GS-IB4) (Invitrogen) and 1,1'-Dioctadecyl-3,3',3'-tetramethyl indocarbocyanine perchlorate-labeled acetylated low-density lipoprotein (DiI-acLDL) (Biomedical Technologies, Wisconsin, USA) as previously described (5). In brief, after removing the methylcellulose by gently washing with ice-cold PBS twice, 1 mL of EBM-2 (Lonza, Basel, Switzerland) medium (5% fetal bovine serum) containing 10 μL of DiI-acLDL and 2 μL of Alex-488-conjugated GS-IB4 was added and further incubated for 3-5 h. After staining the colonies with 4',-6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, California, USA), cells were photographed through a fluorescence microscope (IX70; Olympus, Tokyo, Japan).

3. Results

3.1. Assessment of LF-mice model

In control mice, surfaces of the liver sections were smooth, and fatty changes, characterized by large droplets in hepatocytes, were observed (Figures 1A and 1B). On the other hand, in the LF group, surfaces of the liver sections were irregular, bridging fibrosis, pseudolobule formation, and micronodular formation (Figures 1C and 1D). Splens of CCl₄ injected mice were larger than those of the control group (Table 1). The ratio of spleen weight/body weight was significantly increased in CCl₄ mice, compared with control mice ($p < 0.005$). Serum AST, ALT, and ALP were significantly increased in CCl₄ mice compared with control mice ($p < 0.005$) (Table 2). However, there were no significant difference in mice serum γ -GTP, total bilirubin, total protein, albumin, and HA levels (data not shown). Finally, LF was clearly evident in all mice injected with CCl₄.

3.2. Impaired commitment and differentiation potentials of BM-KSL cells in LF mice

EPC colony forming activity of BM-KSL cells was performed by EPC colony-forming assay to

morphologically detect two types of EPC-CFUs, that is, primitive EPC-CFU and definitive EPC-CFU with small round and large spindle cells, respectively as previously described (16) (Figure 2). Both types of EPC-CFUs featured typical endothelial aspects of acLDL-DiI uptake and isolectin B4-FITC binding (Figures 2C and 2F).

In the EPC-colony forming assay of BM-KSL cells, the number of definitive EPC-CFU ($p < 0.0001$) and total EPC-CFU ($p < 0.05$) significantly decreased in LF mice, compared with controls, although primitive EPC-CFU did not differ between groups (Figure 3). These findings indicate that the differentiation potentials of BM-KSL cells into endothelial lineage are impaired in LF mice.

3.3. Attenuated EPC differentiation potential in circulation of LF mice

In the EPC-colony forming assay of WB-MNCs, the number of definitive EPC-CFU ($p < 0.005$) and total EPC-CFU ($p < 0.01$) significantly decreased in LF mice, compared with controls, although primitive EPC-colony forming cells did not differ between groups (Figure 4).

4. Discussion

In the current study, we successfully prepared an LF-




Figure 1. Liver fibrosis was observed in all mice injected with carbon tetrachloride (CCl₄). (A) and (B) Control mice (Azan stain: A, $\times 4$; B, $\times 10$). (C) and (D) CCl₄ mice (Azan stain: C, $\times 4$; D, $\times 10$)

Table 1. Spleen weight/body weight ratios in LF and control mice

Group	Spleen weight (mg) (Mean \pm S.E.M.)	Spleen weight/Body weight (Mean \pm S.E.M.)
Control	82.7 \pm 3.6	2.86 \pm 0.13
LF	93.5 \pm 3.5	3.58 \pm 0.13*

* $p < 0.005$ vs. control mice.

Table 2. The serum AST, ALT, and ALP levels in LF and control mice

Group	AST (IU/L)	ALT (IU/L)	ALP (IU/L)
Control	23.1 \pm 2.1	20.4 \pm 3.8	152.6 \pm 3.5
LF	233.8 \pm 2.4*	207.1 \pm 38.9*	201.6 \pm 5.7*

* $p < 0.005$ vs. control mice.




Figure 2. EPC colony-forming assay revealed two distinct colonies. (A) and (B) Primitive EPC colony (A, $\times 4$; B, $\times 10$). (C) and (F) Both colonies expressed acLDL (red), isolectin B4 (green), and DAPI (blue) cells (C and F, merge $\times 20$). (D) and (E) Definitive EPC colony (D, $\times 4$; E, $\times 10$).




Figure 3. In BM-KSL cells, the number of definitive EPC colony-forming-units was significantly decreased in LF-mice. (A) Number of primitive EPC colony-forming-units. (B) Number of definitive EPC colony-forming-units. (C) Number of total EPC colony-forming-units. Control group ($n = 9$), LF group ($n = 13$). * $p < 0.05$, ** $p < 0.0001$ vs. control mice.




Figure 4. In WB-MNCs, the number of definitive EPC colony-forming-units was significantly decreased in LF-mice. (A) Number of primitive EPC colony-forming-units. (B) Number of definitive EPC colony-forming-units. (C) Number of total EPC colony-forming-units. Control group ($n = 4$), LF group ($n = 13$). * $p < 0.01$, ** $p < 0.005$ vs. control mice.

mice model *via* CCl₄ administration to evaluate EPC kinetics in LF using an EPC colony forming assay. Results showed that in BM and within the circulation of LF mice, the frequency of primitive colony forming EPC was not attenuated, but that of definitive colony forming EPC was significantly decreased, resulting in a decreased number of whole colonies forming EPC in LF-mice *versus* controls. These findings indicate that the function of EPC differentiation is downregulated in LF mice.

Chronic inflammatory LF induces vascular remodeling exerted by proangiogenic growth factors produced under hypoxic conditions *via* inadequate blood supply triggered by fibrotic tissue in humans (16). Based on the progression of LF, the replacement of functional hepatocytes with an excess amount of extracellular matrix is considered to decrease the production of proangiogenic growth factors or cytokines, such as vascular endothelial growth factor (17), cyclooxygenase-2-induced eicosanoids (18), hepatocyte growth factor (19), and thrombopoietin (20).

Various studies have demonstrated the pivotal roles of BM-derived EPCs, including their role in postnatal vasculogenesis, that is, mobilization, differentiation, and in foci recruitment, and shown that these cells are upregulated by proangiogenic growth factors, cytokines, and hormones (2). Previous reports show that EPC induce vasculogenesis and repair the injured tissues in several diseases (21,22). One of the mechanisms of this effect is that EPCs express several growth factors that exert paracrine effects for tissue regeneration, including hepatocyte growth factor, vascular endothelial growth factor, and transforming growth factor- α (23). Therefore, it is predicted that disturbed EPC differentiation might give rise to inadequate production for tissue regeneration, although the productivity of growth factors accompanying EPC differentiation need to be investigated.

Alternatively, it has recently been reported that the physiological homeostasis of EPC function is impaired in patients with diabetes (5), hypertension (24), hyperlipidemia (6), rheumatic disease (9), Alzheimer disease (11), aging, and smoking (7). In these conditions, oxidative stress is a key factor in inducing senescence or apoptosis of EPCs, resulting in impairments of physiological functions of EPC (25). Also, oxidative stress has been demonstrated to be a major inducer of pathological progression into LF in chronic liver disease as well (26). Therefore, in the present study, it is understandable that oxidative stress causing LF may impair EPC differentiation potential, as previously discussed in diabetes (16,27).

A therapeutic vascular improvement induced by using EPCs for chronic lower-limb ischemia including arteriosclerosis obliterans or Burger's disease, as well as myocardial infarction or angina pectoris, has been identified (28). In the field of liver regeneration therapy, autologous bone marrow cell infusion therapy, using

MNC (so-called non-selected EPCs), or selected EPCs (CD34⁺ or CD133⁺) has been used to treat liver cirrhosis patients in clinical studies, and favorable therapeutic efficacy has been reported (29,30). However, although accumulating evidence has indicated that EPC therapy may be a useful treatment for liver cirrhosis patients, there have been few reports on EPC kinetics during the development of LF.

Our study demonstrated that the homeostasis of EPC function was disrupted in LF, indicating a weakened regenerative capability. Given these results, it appears necessary to precisely and adequately investigate the efficacy of autologous bone marrow cell infusion using 'naïve EPCs' or to develop a novel strategy for improvement of EPC differentiation potential. Regarding this, G-CSF is reported to promote VEGF secretion from neutrophil for angiogenesis (31). Accordingly, the administration of G-CSF may be considered as one of strategies to repair its potential by induction of EPC differentiation as well as mobilization, because VEGF augments EPC differentiation and mobilization (32). The transplantation of EPCs after G-CSF administration may further enhance the recovery from LF. Alternatively, *ex vivo* culture system to improve the impaired EPC function, when successfully developed, might be another promising strategy.

In conclusion, LF exhibits impaired EPC commitment and differentiation potentials, providing information applicable not only for the pathological diagnosis, but also for the development of an effective EPC therapy.

Acknowledgements

We greatly thank Dr. Yutaka Inagaki and Dr. Reiichi Higashiyama (Research Unit for Tissue Remodeling and Regeneration in Tokai University School of Medicine) for technical advices in preparation of murine LF model by CCl₄ injection, Dr. Hiroyuki Aikawa (Department of Basic Clinical Science and Public Health in Tokai University School of Medicine) for confirming the permissible range of CCl₄ level in room air. We also thank members of the Teaching and Research Support Center of Tokai University for their meticulous care of the experimental animals and the technical support of cell sorting. This work was supported by a Grant-in-Aid for Research of the Science Frontier Program and a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. *Science*. 1997; 275:964-967.
2. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: Mobilization, differentiation, and homing. *Arterioscler Thromb Vasc Biol*. 2003; 23:1185-1189.

3. Masuda H, Kalka C, Takahashi T, *et al.* Estrogen-mediated endothelial progenitor cell biology and kinetics for physiological postnatal vasculogenesis. *Circ Res.* 2007; 101:598-606.
4. Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. *Catheter Cardiovasc Interv.* 2007; 70:477-484.
5. Fadini GP, Agostini C, Avogaro A. Endothelial progenitor cells and vascular biology in diabetes mellitus: Current knowledge and future perspectives. *Curr Diabetes Rev.* 2005; 1:41-58.
6. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH, Zhu JH. Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. *Clin Sci (Lond).* 2004; 107:273-280.
7. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, Inden Y, Murohara T. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. *Arterioscler Thromb Vasc Biol.* 2004; 24:1442-1447.
8. Masuda J, Mitsuyama K, Yamasaki H, Takedatsu H, Okamura T, Andoh A, Murohara T, Asahara T, Sata M. Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. *Int J Mol Med.* 2007; 19:221-228.
9. Avouac J, Uzan G, Kahan A, Boileau C, Allanore Y. Endothelial progenitor cells and rheumatic disorders. *Joint Bone Spine.* 2008; 75:131-137.
10. de Groot KD, Bahlmann FH, Sowa J, Koenig J, Menne J, Haller H, Fliser D. Uremia causes endothelial progenitor cell deficiency. *Kidney Int.* 2004; 66:641-646.
11. Lee ST, Chu K, Jung KH, Park HK, Kim DH, Bahn JJ, Kim JH, Oh MJ, Lee SK, Kim M, Roh JK. Reduced circulating angiogenic cells in Alzheimer disease. *Neurology.* 2009; 72:1858-1863.
12. Inagaki Y, Higashi K, Kushida M, Hong YY, Nakao S, Higashiyama R, Moro T, Itoh J, Mikami T, Kimura T, Shiota G, Kuwabara I, Okazaki I. Hepatocyte Growth factor suppresses profibrogenic signal transduction *via* nuclear export of Smad3 with galectin-7. *Gastroenterology.* 2008; 134:1180-1190.
13. Kwon SM, Suzuki T, Kawamoto A, Ii M, Eguchi M, Akimaru H, Wada M, Matsumoto T, Masuda H, Nakagawa Y, Nishimura H, Kawai K, Takaki S, Asahara T. Pivotal role of Ink adaptor protein in endothelial progenitor cell biology for vascular regeneration. *Circ Res.* 2009; 104:969-977.
14. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res.* 1999; 85:221-228.
15. Tanaka R, Wada M, Kwon SM, Masuda H, Carr J, Ito R, Miyasaka M, Warren SM, Asahara T, Tepper OM. The effects of flap ischemia on normal and diabetic progenitor cell function. *Plast Reconstr Surg.* 2008; 121:1929-1942.
16. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. *Hepatology.* 2004; 39:1185-1195.
17. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *EMBO J.* 1999; 18:3964-3972.
18. Kuwano T, Nakao S, Yamamoto H, Tuneyoshi M, Yamamoto T, Kuwano M, Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. *FASEB J.* 2004; 18:300-310.
19. Asano Y, Iimuro Y, Son G, Hirano T, Fujimoto J. Hepatocyte growth factor promotes remodeling of murine liver fibrosis, accelerating recruitment of bone marrow-derived cells into the liver. *Hepatology.* 2007; 37:1080-1094.
20. Eguchi M, Masuda H, Kwon SM, Shirakura K, Shizuno T, Ito R, Kobori M, Asahara T. Lesion-targeted thrombopoietin potentiates vasculogenesis by enhancing motility and enlivenment of transplanted endothelial progenitor cells *via* activation of Akt/mTOR/p70S6kinase signaling pathway. *J Mol Cell Cardiol.* 2008; 45:661-669.
21. Asahara T. Stem cell biology for vascular regeneration. *Ernst Schering Res Found Workshop.* 2005; (54):111-129.
22. Khoo CP, Pozzilli P, Alison MR. Endothelial progenitor cells and their potential therapeutic applications. *Regen Med.* 2008; 3:863-876.
23. Ueno T, Nakamura T, Torimura T, Sata M. Angiogenic cell therapy for hepatic fibrosis. *Med Mol Morphol.* 2006; 39:16-21.
24. Pirro M, Schillaci G, Menecali C, Bagaglia F, Paltriccia R, Vaudo G, Mannarino MR, Mannarino E. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34⁺ cells of hypertensive patients. *J Hypertens.* 2007; 25:2093-2099.
25. Case J, Ingram DA, Haneline LS. Oxidative stress impairs endothelial progenitor cell function. *Antioxid Redox Signal.* 2008; 10:1895-1907.
26. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. *Free Radic Biol Med.* 2003; 34:1-10.
27. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. *Circulation.* 2002; 106:2781-2786.
28. Shantsila E, Watson T, Lip GY. Endothelial progenitor cells in cardiovascular disorders. *J Am Coll Cardiol.* 2007; 49:741-752.
29. Terai S, Ishikawa T, Omori K, Aoyama K, Marumoto Y, Urata Y, Yokoyama Y, Uchida K, Yamasaki T, Fujii Y, Okita K, Sakaida I. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. *Stem Cells.* 2006; 24:2292-2298.
30. Mohamadnejad M, Namiri M, Bagheri M, Hashemi SM, Ghanaati H, Zare Mehrjardi N, Kazemi Ashtiani S, Malekzadeh R, Baharvand H. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. *World J Gastroenterol.* 2007; 28:3359-3363.
31. Ohki Y, Heissig B, Sato Y, Akiyama H, Zhu Z, Hicklin DJ, Shimada K, Ogawa H, Daida H, Hattori K, Ohsaka A. Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. *FASEB J.* 2005; 19:2005-2007.
32. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells *via* the PI 3-kinase/Akt pathway. *J Clin Invest.* 2001; 108:391-397.

(Received March 5, 2011; Revised April 10, 2011; Accepted April 12, 2011)

Immunohistochemical characterization of the cellular infiltrate in discoid lupus erythematosus

Yong Xie, Masatoshi Jinnin, Xiaoyong Zhang, Shoji Wakasugi, Takamitsu Makino, Yuji Inoue, Satoshi Fukushima, Shinichi Masuguchi, Keisuke Sakai, Hironobu Ihn*

Department of Dermatology & Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

Summary

Discoid lupus erythematosus (DLE) is a chronic connective tissue disease of unknown etiology, but immunologic factors may play an important role in the pathogenesis. We investigated the features of immunohistochemical characterization of the cellular infiltrate in DLE. Skin samples were obtained from 5 patients using a 6 mm punch biopsy. Samples were stained with monoclonal antibodies against CD1a, CD3, CD4, CD8, CD20, CD25, CD30, and CD57. The number of cells stained with each monoclonal antibody was calculated. The number of cells stained with each monoclonal antibody in the dermis infiltration in DLE was calculated and all were higher than those in the normal control. The numbers of CD3⁺, CD4⁺, CD8⁺, CD20⁺, CD25⁺, or CD57⁺ cells in DLE were statistically higher than those in normal skin ($p < 0.05$). The numbers of CD1a⁺ and CD30⁺ cells in DLE were appreciably increased but had no statistical significance compared with normal skin. In conclusion, this study revealed that T lymphocytes, B lymphocytes, and natural killer cells may play some roles in the pathogenesis of DLE.

Keywords: CD panel antibodies, immunohistochemistry, T cells, B cells, natural killer cells

1. Introduction

In 1882 Kaposi (1) distinguished discoid lupus erythematosus (DLE) from the systemic form (SLE). The term discoid is used to describe a coin-shaped, dark to erythematous scaly lesion. Keratinous plugs, whitish depressed areas (atrophy), and telangiectases are also commonly seen. Hypo- and hyper-pigmentation are often residual findings (2). Discoid lesions are not exclusive for DLE; they are observed in 15-30% of SLE patients (2,3). Only 5-10% of adult patients with DLE develop SLE (3). Most adult patients with DLE are between the ages of 20 and 60 years (4), and the female/male ratio is 2:1 to 3:1 (5).

There is evidence for systemic immune disturbance in DLE patients, as judged by the findings of an increased CD4/CD8 ratio in the peripheral blood compared with healthy controls, hypergammaglobulinaemia, and the

presence of autoantibodies (6,7).

In classic DLE lesions, epidermal changes include hyperkeratosis and variable atrophy. Dermal changes include a dense mononuclear cell infiltrate which usually consists of lymphocytes and plasma cells predominantly in the periappendageal and perivascular area. In active lesions, the infiltrate can be found approximating the dermal-epidermal junction associated with hydropic degeneration. A patchy inflammatory infiltrate also may be present in the upper dermis in an interstitial pattern and around eccrine coils. The infiltrate is often quite dense and typically extends well into the deeper reticular dermis and/or subcutis (8,9).

The purpose of our experiments is to investigate primarily the immunohistochemical characterization of the cellular infiltrate in patients with DLE.

2. Materials and Methods

2.1. Patients

Five patients with DLE were randomly chosen for this study, and the disease was confirmed by clinical and pathological examination. Three patients were

*Address correspondence to:

Dr. Hironobu Ihn, Department of Dermatology & Plastic Surgery, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan.
e-mail: ihn-der@kumamoto-u.ac.jp

males, and the rest were females. Mean age was 38.6 years. Three normal specimens as controls were also obtained from age- and sex-matched healthy volunteers. Institutional review board approval and written informed consent were obtained according to the Declaration of Helsinki.

2.2. Cutaneous samples

A skin fragment of the lesion was obtained from each patient by biopsy. The specimen was fixed in 10% formalin for 24 h and processed by routine procedures for embedding in paraffin. Histological sections (4 μ m) were stained with hematoxylin/eosin (HE). The remaining material was used for immunohistochemical analysis.

2.3. Immunohistochemistry

Serial sections were prepared from formalin-fixed, paraffin-embedded skin samples. Monoclonal antibodies (mAb) specific for CD1a (1590, Immunotech, Marseille, France), CD3 (PS1, Novocastra Laboratories, Newcastle, UK), CD4 (IF6, Novocastra Laboratories), CD8 (C8/144, Dako, Glostrup, Denmark), CD20 (NJ1, Novocastra Laboratories), CD25 (4C9, Novocastra Laboratories), CD30 (182, Novocastra Laboratories), CD57 (NK1, Novocastra Laboratories) were used for primary staining. Secondary staining was performed using the LSAB2 staining kit (Dako) for 30 min at room temperature.

Serial 4 μ m thick sections were mounted on silane slides (Dako) and submitted to fixation, deparaffinization in xylene and rehydration through graded alcohols. The antigen was retrieved in 0.1 M Tris-HCl buffer (pH 9.5, containing 5% urea) using a microwave oven for 15 min, each for antigen recovery of the molecules. After cooling to room temperature for 50 min, the slides were treated with 0.3% hydrogen peroxide in methanol (Merck, Darmstadt, Germany) for 30 min to block endogenous peroxidases. Nonspecific staining was blocked with 5% normal horse serum for 30 min. Subsequently the slides were incubated with the primary antibodies diluted in horse serum albumin at 4°C overnight in a humidified chamber. The samples were treated with biotinylated secondary antibody (horse anti-mouse) for 30 min. After washing with PBS, the slides were incubated with ABC reagent for 60 min at room temperature. The slides were then stained with DAB solution for 2-4 min under a microscope at room temperature. Finally the reaction was terminated by washing in distilled water. The slides were washed with PBS between each reaction step. Samples in which the primary antibody was omitted were used as a negative control. Positive labeling was identified by a brown staining around the

cell membrane or by a brown color of the cytoplasm according to the marker employed.

All sections were examined in an Olympus BX50 light microscope (Tokyo, Japan) and results were expressed as the mean count of cells per 10 high-power fields (400 \times). Ten microscopic fields, representing the densest cellular inflammatory infiltrate, were selected per specimen and positive cell numbers were estimated as a proportion of lesion area, using a point counting method.

The scale corresponded to the percentage of stained cells with specific antibody each time, compared to the total cellular infiltration and counting was scored as following: -, no cells (negative); +, few cells (0~10%, weak); ++, some cells (10~25%, moderate); +++, many cells (25~50%, intense); +++++, plenty of cells (more than 50%, very intense).

2.4. Statistical analysis

All the data were collected, classified and entered into a spreadsheet for statistical analysis, using the *t*-test. The dermal infiltration of DLE and normal skin were compared for the following cell counts (per HPF): CD1a, CD3, CD4, CD8, CD4/CD8, CD20, CD25, CD30, and CD57. Results are given as mean \pm S.D. *p* < 0.05 was considered significant.

3. Results

3.1. Evaluation of CD4/CD8 ratio

The CD4/CD8 cell ratio is known to be an indicator of the host immunoregulatory status. The ratio of CD4/CD8 ranged from 0.7 to 1.7 in the five DLE patients. The mean was 1.0 (Table 1), and there was no statistical significance compared to that in normal skin (1.1).

3.2. The percentage of each positive cell in the infiltrates

Examining serial sections, light microscopy revealed that the inflammatory response was concentrated perivascular and periappendageal. The infiltrates consisted mostly of lymphocytes and plasma cells. The percentages of positive cells for each CD antibody are listed in Table 2.

The CD1a mAb stained all five lesions. Most of them (4/5) showed weak infiltration with a mean percentage of 6.7%. Besides the infiltrate in the dermis, there were also many CD1a⁺ cells in the epidermis (not calculated). Representative pictures are shown in Figures 1A and 1B.

The CD3 mAb stained all five sections to a very intense degree. The mean percentage was 69.0%. The pictures are given in Figures 1C and 1D.

The CD4 and CD8 mAb stained all five lesions to an intense degree and the mean percentage of CD4 was

Table 1. CD4/CD8 ratio in the lesions examined

Patient No.	1	2	3	4	5	Mean	Control	p value
CD4/CD8 ratio*	1.7	0.8	0.9	0.7	0.9	1.0	1.1	> 0.05

* The number of CD4⁺ cells divided by the number of CD8⁺ cells.

Table 2. The percentage of each positive cells in the infiltrates

Cell counts	CD1a	CD3	CD4	CD8	CD20	CD25	CD30	CD57
-	0	0	0	0	0	0	1	0
+	4	0	0	0	2	4	4	2
++	1	0	0	0	3	1	0	3
+++	0	0	5	5	0	0	0	0
++++	0	5	0	0	0	0	0	0
Mean (%)	6.7	69.0	34.5	37.8	11.6	7.5	3.5	11.3

-, negative; +, weak (0~10%); ++, moderate (10~25%); +++, intense (25~50%); +++++, very intense (> 50%).




Figure 1. Immunohistochemical staining of CD panel antibodies. The anti-CD1a mAb stained a few infiltrate cells around many lymphocytes in DLE (A, normal skin; B, DLE). The anti-CD3 mAb stained many infiltrate cells in the dermis (C, normal skin; D, DLE). The anti-CD4 mAb stained many infiltrate cells around vessels (E, normal skin; F, DLE). The anti-CD8 mAb stained many infiltrate cells around vessels (G, normal skin; H, DLE). The anti-CD20 mAb stained some infiltrate cells among the lymphocytes (I, normal skin; J, DLE). The anti-CD25 mAb stained a few infiltrate cells around vessels (K, normal skin; L, DLE). The anti-CD30 mAb stained only a few infiltrate cells around many lymphocytes (M, normal skin; N, DLE). The anti-CD57 mAb stained some infiltrate cells among many lymphocytes (O, normal skin; P, DLE). Original magnification, $\times 100$.

34.5%, while that of CD8 was 37.8%. The expressions of the two mAbs are exhibited in Figures 1E, 1F, 1G, and 1H.

CD20 positive cells were observed in all five skin lesions. Two of them were weak, the other three were moderate. The mean percentage was 11.6%. The

pictures are shown in Figures 1I and 1J.

CD25⁺ cell infiltrates were weak in four sections and moderate in one with a mean percentage of 9.4%. Representative pictures are shown in Figures 1K and 1L.

The CD30 mAb stained four lesions to a weak degree, while the other was negative. The mean

percentage was less than 3.5%. The expression of CD30 is exhibited in Figures 1M and 1N.

CD57⁺ cell infiltrates were weak in two and moderate in three with a mean percentage of 11.3%. The pictures are shown in Figures 1O and 1P.

3.3. Positive cell numbers of immunostaining with anti-CD1a, anti-CD3, anti-CD4, anti-CD8, anti-CD20, anti-CD25, anti-CD30, and anti-CD57 mAbs

All lesional skins showed dermal perivascular and periappendageal infiltration. The results of numbers for each positive cell in per HPF are summarized in Table 3. The numbers of CD3⁺ (94.1 ± 51.8), CD4⁺ (48.3 ± 18.2), CD8⁺ (55.9 ± 27.9), CD20⁺ (21.3 ± 16.4), CD25⁺ (6.7 ± 1.9), and CD57⁺ (11.8 ± 4.8) cells in DLE were significantly higher than those in normal skin ($p < 0.05$). Although the numbers of CD1a (2.3 ± 1.3) and CD30⁺ (4.0 ± 3.3) cells in DLE were also higher than those in normal skin, there was no statistical difference between them.

4. Discussion

DLE is a connective tissue disorder characterized by well-demarcated, erythematous, slightly infiltrated "discoid" plaques that often show adherent thick scales and follicular plugging. The etiology of DLE is still unknown but considered to be multifactorial at this time. Immunologic factors may play an important role in its pathogenesis. In active lesions, the dense inflammatory infiltrate is observed in the dermal-epidermal junction. The infiltrate in dermis is often quite dense in the periappendageal and perivascular area and typically extends well into the deeper reticular dermis and subcutis.

The present immunohistochemical study was conducted to show the features of a panel of CD monoclonal antibodies in dermal infiltrate in the skin of DLE patients.

Analysis of the lymphocyte population by immunohistochemistry revealed a conspicuous infiltrate of T lymphocytes in the dermis of DLE patients which

were usually observed around appendices and blood vessels. CD3 positive cells were found in the dermal infiltrate of all biopsies and showed a considerable percentage in the infiltrating area (69.0%). The number of CD3⁺ T cells per HPF (94.1 ± 51.8) in DLE was significantly higher than that in normal skin (5.8 ± 5.3 , $p < 0.05$). Amoura *et al.* (10) suggested that chronic discoid lupus erythematosus (CDLE), the most common clinical subtype of cutaneous lupus erythematosus (CLE), was characterized by a dense lymphocytic infiltrate composed of CD3⁺ lymphocytes with a slight predominance of CD4⁺ over CD8⁺.

T lymphocytes are critical as mediators of inflammation immunity through the combined activity of CD8⁺ and CD4⁺ cells. Immunohistochemical analysis of different subsets of T cells revealed the host immunoregulatory status. There are many more CD4⁺ T cells (48.3 ± 18.2) and CD8⁺ T cells (55.9 ± 27.9) in the dermal infiltration than those of normal controls (2.9 ± 1.0 and 2.5 ± 0.6 , respectively). It was detected that the number of CD8⁺ cells were appreciably higher than CD4⁺ cells in the DLE lesions. This was appreciably different from other authors (11,12), but a similar result was also obtained by Wenzel *et al.* (13). The CD4/CD8 ratio, which ranged approximately from 0.7 to 1.7 (mean 1.0), was a slight decrease compared to that in normal skin (1.1), but there was no statistical significance between them. Wouters *et al.* (14) studied the circulating lymphocyte profiles in patients with DLE and found that the levels of CD4⁺ T cells were similar in DLE patients and healthy controls, but that CD8⁺ T cells were decreased both in absolute numbers and percentages, which resulted in a mild increase of the CD4/CD8 ratio. The decreased number of circulating CD8⁺ T cells found in their study might result from a shift of these cells to the skin that may be involved in T-cell mediated cytotoxic damage of basal keratinocytes. This may be compatible with the immunohistological finding of CD8⁺ T cells close to damaged keratinocytes in lesional epidermis (14).

In this study we determined the presence of B lymphocytes in cutaneous lesions based on the CD20 marker. CD20 is a protein solely expressed on B

Table 3. Results of immunohistochemical staining

CD mAb	Patients (n = 5)	Control (n = 3)	p value
CD1a ⁺ (per HPF dermis)	2.3 ± 1.3	1.1 ± 0.1	> 0.05
CD3 ⁺ (per HPF dermis)	94.1 ± 51.8	5.8 ± 5.3	< 0.05
CD4 ⁺ (per HPF dermis)	48.3 ± 18.2	2.9 ± 1.0	< 0.05
CD8 ⁺ (per HPF dermis)	55.9 ± 27.9	2.5 ± 0.6	< 0.05
CD4/CD8 ratio	1.0 ± 0.4	1.1 ± 0.2	> 0.05
CD20 ⁺ (per HPF dermis)	21.3 ± 16.4	0.6 ± 0.9	< 0.05
CD25 ⁺ (per HPF dermis)	6.7 ± 1.9	2.5 ± 1.8	< 0.05
CD30 ⁺ (per HPF dermis)	4.0 ± 3.3	0.5 ± 0.7	> 0.05
CD57 ⁺ (per HPF dermis)	11.8 ± 4.8	2.4 ± 0.6	< 0.05

Data are mean ± S.D. $p < 0.05$ was considered statistical significance.

lymphocytes (15). In our sections, B cells were found in perivascular aggregates, surrounded by T lymphocytes. The number of CD20⁺ cells (21.3 ± 16.4) in the infiltration of DLE lesions was significantly higher than that in normal skin (0.6 ± 0.9) and there was a statistical significance ($p < 0.05$). The mean percentage of CD20⁺ cells was 11.6% of the inflammatory cells. Previous studies reported that B lymphocytes were rare or absent (< 5%) in DLE lesions (11,16-18). However, Akasu *et al.* observed B lymphocytes accounted for > 25% in one of his five DLE cases (19). Wolfgang *et al.* found B lymphocytes were over 5% of the inflammatory cells in 31% of their DLE cases and in 8 of 49 cases, and that B lymphocytes accounted for > 20% of the inflammatory cell infiltrate. In short, our study substantiated Akasu and Wolfgang's findings that numerous B lymphocytes may be found in DLE lesions. In a circulating lymphocyte study (14), the percentage of CD19⁺ B cells was increased in DLE patients compared with healthy controls, which was compatible with earlier studies that demonstrated increased percentages of cytoplasmic immunoglobulin-containing and immunoglobulin-secreting cells in the DLE peripheral blood. The role of B lymphocytes in DLE is unknown, but local secretion of specific antibodies is possible, which may act through mechanisms such as opsonization and activation of the complement system.

CD25 is the marker for human interleukin (IL)-2 receptor. In this study the percentage of CD25⁺ cells in dermal inflammatory cells was relatively low (6.7 ± 1.9), just as previously described by other authors (11,20,21), however, it was slightly increased compared to that in normal skin (2.5 ± 1.8) and there was statistical significance. Following the activation of T cells with antigen or mitogen in the presence of the IL-1, IL-2 is rapidly synthesized and secreted. In response to this, a subpopulation of T cells expresses high affinity receptors for IL-2. These cells proliferate and expand the T cell population which is capable of mediating helper, suppressor and cytotoxic functions. The activation of T lymphocytes by IL-2 suggests that non-specific, non-major histocompatibility complex (MHC)-restricted mechanisms of cellular cytotoxicity is involved in the pathogenesis of the skin lesions in LE (11).

CD30 or Ki-1 antigen expression was rarely seen in dermal DLE infiltration. Comparably, normal skin controls in this study showed less positive findings. CD30 has been suggested to be a marker for Th2 cells (22). Our result indicates that the Th2 cells may not be included in the dermal immunoreaction in DLE.

We found an increased number (11.8 ± 4.8) and percentage (11.3%) of CD57⁺ NK cells in DLE compared with normal skin and there was statistical significance. NK cells are thought to play an important role in tissue damage as well as in modulation of B cell activity (23). Wouters *et al.* (14) found a lower number of CD57⁺ cells in peripheral blood in DLE.

They hypothesized that the reduction of these subsets in peripheral blood may be the result of skin recruitment. Our result provided evidence for their hypothesis. Their study proved the systemic activation of the cellular immune system in DLE.

The result of this study revealed that T lymphocytes, B lymphocytes cells, and natural killer cells may play some roles in DLE pathogenesis. The inflammatory effector mechanisms of DLE may be confined to the skin and mediated by T cells, B cells, and NK cells which may migrate from the circulation to the site of inflammation. The number of patients included in this study was not large. Further studies are needed to analyze the *in situ* participation of key cytokines on these cells to better understand the pathogenesis of this disease.

References

1. Kaposi M. Pathologic und Therapie der Hautkrankheiten. 2nd ed., Urban and Schwarzenberg, Vienna, Austria, 1882.
2. Watson R. Cutaneous lesions in systemic lupus erythematosus. *Med Clin North Am.* 1989; 73:1091-1111.
3. Hymes SR, Jordon RE. Chronic cutaneous lupus erythematosus. *Med Clin North Am.* 1989; 73:1055-1071.
4. Peterson R, Good V. Lupus erythematosus. *Pediatr Clin North Am.* 1963; 10:941-978.
5. Prystowsky SD, Herndon JH Jr, Gilliam JN. Chronic cutaneous lupus erythematosus (DLE) – a clinical and laboratory investigation of 80 patients. *Medicine (Baltimore).* 1976; 55:183-191.
6. Wangel AG, Johansson E, Ranki A. Polyclonal B-cell activation and increased lymphocyte helper-suppressor ratios in discoid lupus erythematosus. *Br J Dermatol.* 1984; 110:665-669.
7. Kind P, Lipsky PE, Sontheimer RD. Circulating T- and B-cell abnormalities in cutaneous lupus erythematosus. *J Invest Dermatol.* 1986; 86:235-239.
8. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. *Fitzpatrick's Dermatology in General Medicine.* 6th ed., Mcgraw-Hill, New York, NY, USA, 2003.
9. Elder DE, Elenitsas R, Johnson BL Jr, Murphy GF, eds. *Lever's Histopathology of the Skin.* 9th ed., Lippincott Williams & Wilkins, Philadelphia, PA, USA, 2005.
10. Amoura Z, Combadiere C, Faure S, Parizot C, Miyara M, Raphaël D, Ghillani P, Debre P, Piette JC, Gorochov G. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. *Arthritis Rheum.* 2003; 48:3487-3496.
11. Tebbe B, Mazur L, Stadler R, Orfanos CE. Immunohistochemical analysis of chronic discoid and subacute cutaneous lupus erythematosus – relation to immunopathological mechanisms. *Br J Dermatol.* 1995; 132:25-31.
12. Wenzel J, Uerlich M, Wörrenkämper E, Freutel S, Bieber T, Tüting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. *Br J Dermatol.* 2005; 153:1011-1015.

13. Wenzel J, Henze S, Wörenkämper E, Basner-Tschakarjan E, Sokolowska-Wojdylo M, Steitz J, Bieber T, Tüting T. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. *J Invest Dermatol.* 2005; 124:1241-1248.
14. Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship. *Br J Dermatol.* 2004; 150:693-700.
15. Mason DY, Comans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen JJ. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. *Am J Pathol.* 1990; 136:1215-1222.
16. Moretti S, Amato L, Massi D, Bianchi B, Gallerani I, Fabbri P. Evaluation of inflammatory infiltrate and fibrogenic cytokines in pseudopelade of Brocq suggests the involvement of T-helper 2 and 3 cytokines. *Br J Dermatol.* 2004; 151:84-90.
17. Andrews BS, Schenk A, Barr R, Friou G, Mirick G, Ross P. Immunopathology of cutaneous human lupus erythematosus defined by murine monoclonal antibodies. *J Am Acad Dermatol.* 1986; 15:474-481.
18. Lee MS, Wilkinson B, Doyle JA, Kossard S. A comparative immunohistochemical study of lichen planus and discoid lupus erythematosus. *Australas J Dermatol.* 1996; 37:188-192.
19. Akasu R, Kahn HJ, From L. Lymphocyte markers on formalin fixed tissue in Jessner's lymphocytic infiltrate and lupus erythematosus. *J Cutan Pathol.* 1992; 19:59-65.
20. Bergroth V, Kontinen YT, Piirainen H, Johansson E, Nordström D, Malmström M. Evaluation of lymphocyte activation in skin lesions of patients with mixed connective tissue disease and discoid lupus erythematosus. *Arch Dermatol Res.* 1988; 280:1-4.
21. Sundqvist KG, Wanger L. Expression of lymphocyte activation markers in benign cutaneous T cell infiltrates. Discoid lupus erythematosus *versus* lichen ruber planus. *Acta Derm Vnereol.* 1989; 69:292-295.
22. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elis MM, Zancuoghi G, Vinante F, Pizzolo G, Romagnani S. Preferential expression of CD30 by human CD4⁺ cells producing Th2-type cytokines. *FASEB J.* 1995; 9:81-86.
23. Kimata H, Shanahan F, Brogan M, Targan S, Saxon A. Modulation of ongoing human immunoglobulin synthesis by natural killer cells. *Cell Immunol.* 1987; 107:74-88.

(Received June 10, 2010; Revised February 17, 2011; Accepted March 21, 2011)

Guide for Authors

1. Scope of Articles

BioScience Trends is an international peer-reviewed journal. BioScience Trends devotes to publishing the latest and most exciting advances in scientific research. Articles cover fields of life science such as biochemistry, molecular biology, clinical research, public health, medical care system, and social science in order to encourage cooperation and exchange among scientists and clinical researchers.

2. Submission Types

Original Articles should be well-documented, novel, and significant to the field as a whole. An Original Article should be arranged into the following sections: Title page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments, and References. Original articles should not exceed 5,000 words in length (excluding references) and should be limited to a maximum of 50 references. Articles may contain a maximum of 10 figures and/or tables.

Brief Reports definitively documenting either experimental results or informative clinical observations will be considered for publication in this category. Brief Reports are not intended for publication of incomplete or preliminary findings. Brief Reports should not exceed 3,000 words in length (excluding references) and should be limited to a maximum of 4 figures and/or tables and 30 references. A Brief Report contains the same sections as an Original Article, but the Results and Discussion sections should be combined.

Reviews should present a full and up-to-date account of recent developments within an area of research. Normally, reviews should not exceed 8,000 words in length (excluding references) and should be limited to a maximum of 100 references. Mini reviews are also accepted.

Policy Forum articles discuss research and policy issues in areas related to life science such as public health, the medical care system, and social science and may address governmental issues at district, national, and international levels of discourse. Policy Forum articles should not exceed 2,000 words in length (excluding references).

Case Reports should be detailed reports of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. Case reports may contain a demographic profile of the patient but usually describe an unusual or novel occurrence. Unreported or unusual

side effects or adverse interactions involving medications will also be considered. Case Reports should not exceed 3,000 words in length (excluding references).

News articles should report the latest events in health sciences and medical research from around the world. News should not exceed 500 words in length.

Letters should present considered opinions in response to articles published in BioScience Trends in the last 6 months or issues of general interest. Letters should not exceed 800 words in length and may contain a maximum of 10 references.

3. Editorial Policies

Ethics: BioScience Trends requires that authors of reports of investigations in humans or animals indicate that those studies were formally approved by a relevant ethics committee or review board.

Conflict of Interest: All authors are required to disclose any actual or potential conflict of interest including financial interests or relationships with other people or organizations that might raise questions of bias in the work reported. If no conflict of interest exists for each author, please state "There is no conflict of interest to disclose".

Submission Declaration: When a manuscript is considered for submission to BioScience Trends, the authors should confirm that 1) no part of this manuscript is currently under consideration for publication elsewhere; 2) this manuscript does not contain the same information in whole or in part as manuscripts that have been published, accepted, or are under review elsewhere, except in the form of an abstract, a letter to the editor, or part of a published lecture or academic thesis; 3) authorization for publication has been obtained from the authors' employer or institution; and 4) all contributing authors have agreed to submit this manuscript.

Cover Letter: The manuscript must be accompanied by a cover letter signed by the corresponding author on behalf of all authors. The letter should indicate the basic findings of the work and their significance. The letter should also include a statement affirming that all authors concur with the submission and that the material submitted for publication has not been published previously or is not under consideration for publication elsewhere. The cover letter should be submitted in PDF format. For example of Cover Letter, please visit <http://www.biosciencetrends.com/downcentre.php> (Download Centre).

Copyright: A signed JOURNAL PUBLISHING AGREEMENT (JPA) form must be provided by post, fax, or as a scanned file before acceptance of the article. Only forms with a hand-written signature are accepted. This copyright will ensure the widest possible dissemination of information. A form facilitating transfer of copyright can be downloaded by clicking the

appropriate link and can be returned to the e-mail address or fax number noted on the form (Please visit [Download Centre](#)). Please note that your manuscript will not proceed to the next step in publication until the JPA Form is received. In addition, if excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article.

Suggested Reviewers: A list of up to 3 reviewers who are qualified to assess the scientific merit of the study is welcomed. Reviewer information including names, affiliations, addresses, and e-mail should be provided at the same time the manuscript is submitted online. Please do not suggest reviewers with known conflicts of interest, including participants or anyone with a stake in the proposed research; anyone from the same institution; former students, advisors, or research collaborators (within the last three years); or close personal contacts. Please note that the Editor-in-Chief may accept one or more of the proposed reviewers or may request a review by other qualified persons.

Language Editing: Manuscripts prepared by authors whose native language is not English should have their work proofread by a native English speaker before submission. If not, this might delay the publication of your manuscript in BioScience Trends.

The Editing Support Organization can provide English proofreading, Japanese-English translation, and Chinese-English translation services to authors who want to publish in BioScience Trends and need assistance before submitting a manuscript. Authors can visit this organization directly at <http://www.iacmhr.com/iac-eso/support.php?lang=en>. IAC-ESO was established to facilitate manuscript preparation by researchers whose native language is not English and to help edit works intended for international academic journals.

4. Manuscript Preparation

Manuscripts should be written in clear, grammatically correct English and submitted as a Microsoft Word file in a single-column format. Manuscripts must be paginated and typed in 12-point Times New Roman font with 24-point line spacing. Please do not embed figures in the text. Abbreviations should be used as little as possible and should be explained at first mention unless the term is a well-known abbreviation (e.g. DNA). Single words should not be abbreviated.

Title Page: The title page must include 1) the title of the paper (Please note the title should be short, informative, and contain the major key words); 2) full name(s) and affiliation(s) of the author(s), 3) abbreviated names of the author(s), 4) full name, mailing address, telephone/fax numbers, and e-mail address of the corresponding author; and 5) conflicts of interest (if you have an actual or potential conflict of interest to disclose, it must be included as a footnote on the title page of the manuscript; if no conflict of

interest exists for each author, please state "There is no conflict of interest to disclose"). Please visit [Download Centre](#) and refer to the title page of the manuscript sample.

Abstract: A one-paragraph abstract consisting of no more than 250 words must be included. The abstract should briefly state the purpose of the study, methods, main findings, and conclusions. Abbreviations must be kept to a minimum and non-standard abbreviations explained in brackets at first mention. References should be avoided in the abstract. Key words or phrases that do not occur in the title should be included in the Abstract page.

Introduction: The introduction should be a concise statement of the basis for the study and its scientific context.

Materials and Methods: The description should be brief but with sufficient detail to enable others to reproduce the experiments. Procedures that have been published previously should not be described in detail but appropriate references should simply be cited. Only new and significant modifications of previously published procedures require complete description. Names of products and manufacturers with their locations (city and state/country) should be given and sources of animals and cell lines should always be indicated. All clinical investigations must have been conducted in accordance with Declaration of Helsinki principles. All human and animal studies must have been approved by the appropriate institutional review board(s) and a specific declaration of approval must be made within this section.

Results: The description of the experimental results should be succinct but in sufficient detail to allow the experiments to be analyzed and interpreted by an independent reader. If necessary, subheadings may be used for an orderly presentation. All figures and tables must be referred to in the text.

Discussion: The data should be interpreted concisely without repeating material already presented in the Results section. Speculation is permissible, but it must be well-founded, and discussion of the wider implications of the findings is encouraged. Conclusions derived from the study should be included in this section.

Acknowledgments: All funding sources should be credited in the Acknowledgments section. In addition, people who contributed to the work but who do not meet the criteria for authors should be listed along with their contributions.

References: References should be numbered in the order in which they appear in the text. Citing of unpublished results, personal communications, conference abstracts, and theses in the reference list is not recommended but these sources may be mentioned in the text. In the reference list, cite the names of all authors when there are fifteen or fewer authors; if there are sixteen or more authors, list the first three

followed by *et al.* Names of journals should be abbreviated in the style used in PubMed. Authors are responsible for the accuracy of the references. Examples are given below:

Example 1 (Sample journal reference):

Inagaki Y, Tang W, Zhang L, Du GH, Xu WF, Kokudo N. Novel aminopeptidase N (APN/CD13) inhibitor 24F can suppress invasion of hepatocellular carcinoma cells as well as angiogenesis. *Biosci Trends*. 2010; 4:56-60.

Example 2 (Sample journal reference with more than 15 authors):

Darby S, Hill D, Auvinen A, *et al.* Radon in homes and risk of lung cancer: Collaborative analysis of individual data from 13 European case-control studies. *BMJ*. 2005; 330:223.

Example 3 (Sample book reference):

Shalev AY. Post-traumatic stress disorder: diagnosis, history and life course. In: *Post-traumatic Stress Disorder, Diagnosis, Management and Treatment* (Nutt DJ, Davidson JR, Zohar J, eds.). Martin Dunitz, London, UK, 2000; pp. 1-15.

Example 4 (Sample web page reference):

Ministry of Health, Labour and Welfare of Japan. Dietary reference intakes for Japanese. <http://www.mhlw.go.jp/houdou/2004/11/h1122-2a.html> (accessed June 14, 2010).

Tables: All tables should be prepared in Microsoft Word or Excel and should be arranged at the end of the manuscript after the References section. Please note that tables should not in image format. All tables should have a concise title and should be numbered consecutively with Arabic numerals. If necessary, additional information should be given below the table.

Figure Legend: The figure legend should be typed on a separate page of the main manuscript and should include a short title and explanation. The legend should be concise but comprehensive and should be understood without referring to the text. Symbols used in figures must be explained.

Figure Preparation: All figures should be clear and cited in numerical order in the text. Figures must fit a one- or two-column format on the journal page: 8.3 cm (3.3 in.) wide for a single column, 17.3 cm (6.8 in.) wide for a double column; maximum height: 24.0 cm (9.5 in.). Please make sure that the symbols and numbers appeared in the figures should be clear. Please make sure that artwork files are in an acceptable format (TIFF or JPEG) at minimum resolution (600 dpi for illustrations, graphs, and annotated artwork, and 300 dpi for micrographs and photographs). Please provide all figures as separate files. Please note that low-resolution images are one of the leading causes of article resubmission and schedule delays. All color figures will be reproduced in full color in the online edition of the journal at no cost to authors.

Units and Symbols: Units and symbols conforming to the International System

of Units (SI) should be used for physicochemical quantities. Solidus notation (*e.g.* mg/kg, mg/mL, mol/mm²/min) should be used. Please refer to the SI Guide www.bipm.org/en/si/ for standard units.

Supplemental data: Supplemental data might be useful for supporting and enhancing your scientific research and BioScience Trends accepts the submission of these materials which will be only published online alongside the electronic version of your article. Supplemental files (figures, tables, and other text materials) should be prepared according to the above guidelines, numbered in Arabic numerals (*e.g.*, Figure S1, Figure S2, and Table S1, Table S2) and referred to in the text. All figures and tables should have titles and legends. All figure legends, tables and supplemental text materials should be placed at the end of the paper. Please note all of these supplemental data should be provided at the time of initial submission and note that the editors reserve the right to limit the size and length of Supplemental Data.

5. Submission Checklist

The Submission Checklist will be useful during the final checking of a manuscript prior to sending it to BioScience Trends for review. Please visit [Download Centre](#) and download the Submission Checklist file.

6. Online Submission

Manuscripts should be submitted to BioScience Trends online at <http://www.biosciencetrends.com>. The manuscript file should be smaller than 5 MB in size. If for any reason you are unable to submit a file online, please contact the Editorial Office by e-mail at office@biosciencetrends.com.

7. Accepted Manuscripts

Proofs: Galley proofs in PDF format will be sent to the corresponding author via e-mail. Corrections must be returned to the editor (proof-editing@biosciencetrends.com) within 3 working days.

Offprints: Authors will be provided with electronic offprints of their article. Paper offprints can be ordered at prices quoted on the order form that accompanies the proofs.

Page Charge: A page charge of \$140 will be assessed for each printed page of an accepted manuscript. The charge for printing color figures is \$340 for each page. The total charge may be reduced or waived in accordance with conditions in the country where the study took place.

(Revised February 2011)

Editorial and Head Office:

Pearl City Koishikawa 603
2-4-5 Kasuga, Bunkyo-ku
Tokyo 112-0003 Japan
Tel: +81-3-5840-8764
Fax: +81-3-5840-8765
E-mail: office@biosciencetrends.com

JOURNAL PUBLISHING AGREEMENT (JPA)

Manuscript No.:

Title:

Corresponding Author:

The International Advancement Center for Medicine & Health Research Co., Ltd. (IACMHR Co., Ltd.) is pleased to accept the above article for publication in BioScience Trends. The International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) reserves all rights to the published article. Your written acceptance of this JOURNAL PUBLISHING AGREEMENT is required before the article can be published. Please read this form carefully and sign it if you agree to its terms. The signed JOURNAL PUBLISHING AGREEMENT should be sent to the BioScience Trends office (Pearl City Koishikawa 603, 2-4-5 Kasuga, Bunkyo-ku, Tokyo 112-0003, Japan; E-mail: office@biosciencetrends.com; Tel: +81-3-5840-8764; Fax: +81-3-5840-8765).

1. Authorship Criteria

As the corresponding author, I certify on behalf of all of the authors that:

- 1) The article is an original work and does not involve fraud, fabrication, or plagiarism.
- 2) The article has not been published previously and is not currently under consideration for publication elsewhere. If accepted by BioScience Trends, the article will not be submitted for publication to any other journal.
- 3) The article contains no libelous or other unlawful statements and does not contain any materials that infringes upon individual privacy or proprietary rights or any statutory copyright.
- 4) I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my article.
- 5) All authors have made significant contributions to the study including the conception and design of this work, the analysis of the data, and the writing of the manuscript.
- 6) All authors have reviewed this manuscript and take responsibility for its content and approve its publication.
- 7) I have informed all of the authors of the terms of this publishing agreement and I am signing on their behalf as their agent.

2. Copyright Transfer Agreement

I hereby assign and transfer to IACMHR Co., Ltd. all exclusive rights of copyright ownership to the above work in the journal BioScience Trends, including but not limited to the right 1) to publish, republish, derivate, distribute, transmit, sell, and otherwise use the work and other related material worldwide, in whole or in part, in all languages, in electronic, printed, or any other forms of media now known or hereafter developed and the right 2) to authorize or license third parties to do any of the above.

I understand that these exclusive rights will become the property of IACMHR Co., Ltd., from the date the article is accepted for publication in the journal BioScience Trends. I also understand that IACMHR Co., Ltd. as a copyright owner has sole authority to license and permit reproductions of the article.

I understand that except for copyright, other proprietary rights related to the Work (*e.g.* patent or other rights to any process or procedure) shall be retained by the authors. To reproduce any text, figures, tables, or illustrations from this Work in future works of their own, the authors must obtain written permission from IACMHR Co., Ltd.; such permission cannot be unreasonably withheld by IACMHR Co., Ltd.

3. Conflict of Interest Disclosure

I confirm that all funding sources supporting the work and all institutions or people who contributed to the work but who do not meet the criteria for authors are acknowledged. I also confirm that all commercial affiliations, stock ownership, equity interests, or patent-licensing arrangements that could be considered to pose a financial conflict of interest in connection with the article have been disclosed.

Corresponding Author's Name (Signature):

Date:

